EP2183253B1 - Thieno-pyridine derivatives as mek inhibitors - Google Patents
Thieno-pyridine derivatives as mek inhibitors Download PDFInfo
- Publication number
- EP2183253B1 EP2183253B1 EP08775964.3A EP08775964A EP2183253B1 EP 2183253 B1 EP2183253 B1 EP 2183253B1 EP 08775964 A EP08775964 A EP 08775964A EP 2183253 B1 EP2183253 B1 EP 2183253B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- compound
- thieno
- fluoro
- amino
- iodophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 title claims description 6
- DBDCNCCRPKTRSD-UHFFFAOYSA-N thieno[3,2-b]pyridine Chemical class C1=CC=C2SC=CC2=N1 DBDCNCCRPKTRSD-UHFFFAOYSA-N 0.000 title description 3
- 238000011282 treatment Methods 0.000 claims abstract description 19
- 230000002062 proliferating effect Effects 0.000 claims abstract description 5
- 230000001363 autoimmune Effects 0.000 claims abstract description 4
- 230000003040 nociceptive effect Effects 0.000 claims abstract description 4
- 230000000771 oncological effect Effects 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims abstract description 3
- 230000002526 effect on cardiovascular system Effects 0.000 claims abstract description 3
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 120
- -1 homopiperidin-1-yl Chemical group 0.000 claims description 64
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 27
- 150000003839 salts Chemical class 0.000 claims description 22
- 239000012453 solvate Substances 0.000 claims description 15
- 125000004122 cyclic group Chemical group 0.000 claims description 14
- 125000001424 substituent group Chemical group 0.000 claims description 14
- 150000001204 N-oxides Chemical class 0.000 claims description 11
- 229910052736 halogen Inorganic materials 0.000 claims description 11
- 150000002367 halogens Chemical group 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 11
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 7
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 6
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 6
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims description 6
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 5
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 125000002346 iodo group Chemical group I* 0.000 claims description 5
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 5
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 claims description 4
- 125000001246 bromo group Chemical group Br* 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 125000004043 oxo group Chemical group O=* 0.000 claims description 3
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 3
- UCBJYIXTHASYAB-LLVKDONJSA-N (3r)-1-[2-(2-fluoro-4-iodoanilino)thieno[2,3-b]pyridin-3-yl]sulfonylpyrrolidin-3-ol Chemical compound C1[C@H](O)CCN1S(=O)(=O)C(C1=CC=CN=C1S1)=C1NC1=CC=C(I)C=C1F UCBJYIXTHASYAB-LLVKDONJSA-N 0.000 claims description 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 2
- KHZWZIWAXNBZMN-UHFFFAOYSA-N 3-(3-aminoazetidin-1-yl)sulfonyl-n-(2-fluoro-4-iodophenyl)thieno[2,3-b]pyridin-2-amine Chemical compound C1C(N)CN1S(=O)(=O)C(C1=CC=CN=C1S1)=C1NC1=CC=C(I)C=C1F KHZWZIWAXNBZMN-UHFFFAOYSA-N 0.000 claims description 2
- HONAXMPGDQVLNW-LLVKDONJSA-N 3-[(3r)-3-aminopyrrolidin-1-yl]sulfonyl-n-(2-fluoro-4-iodophenyl)thieno[2,3-b]pyridin-2-amine Chemical compound C1[C@H](N)CCN1S(=O)(=O)C(C1=CC=CN=C1S1)=C1NC1=CC=C(I)C=C1F HONAXMPGDQVLNW-LLVKDONJSA-N 0.000 claims description 2
- HONAXMPGDQVLNW-NSHDSACASA-N 3-[(3s)-3-aminopyrrolidin-1-yl]sulfonyl-n-(2-fluoro-4-iodophenyl)thieno[2,3-b]pyridin-2-amine Chemical compound C1[C@@H](N)CCN1S(=O)(=O)C(C1=CC=CN=C1S1)=C1NC1=CC=C(I)C=C1F HONAXMPGDQVLNW-NSHDSACASA-N 0.000 claims description 2
- MWKSHKHKIVTZHO-UHFFFAOYSA-N 3-[3-(aminomethyl)azetidin-1-yl]sulfonyl-n-(2-fluoro-4-iodophenyl)thieno[2,3-b]pyridin-2-amine Chemical compound C1C(CN)CN1S(=O)(=O)C(C1=CC=CN=C1S1)=C1NC1=CC=C(I)C=C1F MWKSHKHKIVTZHO-UHFFFAOYSA-N 0.000 claims description 2
- 229940124647 MEK inhibitor Drugs 0.000 claims description 2
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 2
- PUAPBJYHVGMFHX-UHFFFAOYSA-N n-(2-fluoro-4-iodophenyl)-3-piperazin-1-ylsulfonylthieno[2,3-b]pyridin-2-amine;hydrochloride Chemical compound Cl.FC1=CC(I)=CC=C1NC1=C(S(=O)(=O)N2CCNCC2)C2=CC=CN=C2S1 PUAPBJYHVGMFHX-UHFFFAOYSA-N 0.000 claims description 2
- NGOABHUOTGKOLG-UHFFFAOYSA-N n-(2-fluoro-4-iodophenyl)-3-pyrrolidin-1-ylsulfonylthieno[2,3-b]pyridin-2-amine Chemical compound FC1=CC(I)=CC=C1NC1=C(S(=O)(=O)N2CCCC2)C2=CC=CN=C2S1 NGOABHUOTGKOLG-UHFFFAOYSA-N 0.000 claims description 2
- FZLNAAAYMVZSBV-UHFFFAOYSA-N tert-butyl N-[1-[2-(2-fluoro-4-iodoanilino)thieno[2,3-b]pyridin-3-yl]sulfonylazetidin-3-yl]carbamate Chemical compound C(C)(C)(C)OC(NC1CN(C1)S(=O)(=O)C1=C(SC2=NC=CC=C21)NC1=C(C=C(C=C1)I)F)=O FZLNAAAYMVZSBV-UHFFFAOYSA-N 0.000 claims description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- ZCTBUJLBVONGJN-AWEZNQCLSA-N tert-butyl n-[(3s)-1-[2-(2-fluoro-4-iodoanilino)thieno[2,3-b]pyridin-3-yl]sulfonylpyrrolidin-3-yl]carbamate Chemical compound C1[C@@H](NC(=O)OC(C)(C)C)CCN1S(=O)(=O)C(C1=CC=CN=C1S1)=C1NC1=CC=C(I)C=C1F ZCTBUJLBVONGJN-AWEZNQCLSA-N 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 125000004571 thiomorpholin-4-yl group Chemical group N1(CCSCC1)* 0.000 claims description 2
- CWRFJHVYKNPQGS-UHFFFAOYSA-N 1-[2-(2-fluoro-4-iodoanilino)thieno[2,3-b]pyridin-3-yl]sulfonylazetidin-3-ol Chemical compound C1C(O)CN1S(=O)(=O)C(C1=CC=CN=C1S1)=C1NC1=CC=C(I)C=C1F CWRFJHVYKNPQGS-UHFFFAOYSA-N 0.000 claims 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- KQSSATDQUYCRGS-UHFFFAOYSA-N methyl glycinate Chemical compound COC(=O)CN KQSSATDQUYCRGS-UHFFFAOYSA-N 0.000 claims 1
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 abstract description 12
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 abstract description 12
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 abstract description 5
- 229940124639 Selective inhibitor Drugs 0.000 abstract description 3
- SMZMHUCIDGHERP-UHFFFAOYSA-N thieno[2,3-b]pyridine Chemical class C1=CN=C2SC=CC2=C1 SMZMHUCIDGHERP-UHFFFAOYSA-N 0.000 abstract description 3
- 102000004190 Enzymes Human genes 0.000 abstract description 2
- 108090000790 Enzymes Proteins 0.000 abstract description 2
- 230000008901 benefit Effects 0.000 abstract description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 90
- 239000000543 intermediate Substances 0.000 description 38
- 239000000243 solution Substances 0.000 description 33
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 33
- 239000000203 mixture Substances 0.000 description 29
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 27
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 26
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 26
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 25
- 238000000034 method Methods 0.000 description 25
- 239000007787 solid Substances 0.000 description 23
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 239000011541 reaction mixture Substances 0.000 description 20
- 239000002904 solvent Substances 0.000 description 20
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 17
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 16
- 229910052938 sodium sulfate Inorganic materials 0.000 description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- 239000007832 Na2SO4 Substances 0.000 description 13
- 239000000377 silicon dioxide Substances 0.000 description 13
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 235000019439 ethyl acetate Nutrition 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 229910052681 coesite Inorganic materials 0.000 description 7
- 229910052906 cristobalite Inorganic materials 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 229910052682 stishovite Inorganic materials 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 229910052905 tridymite Inorganic materials 0.000 description 7
- 239000003643 water by type Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000001595 flow curve Methods 0.000 description 4
- 125000001153 fluoro group Chemical group F* 0.000 description 4
- 235000019253 formic acid Nutrition 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 150000007530 organic bases Chemical class 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- XTHPWXDJESJLNJ-UHFFFAOYSA-N sulfurochloridic acid Chemical compound OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 4
- XBNGYFFABRKICK-UHFFFAOYSA-N 2,3,4,5,6-pentafluorophenol Chemical compound OC1=C(F)C(F)=C(F)C(F)=C1F XBNGYFFABRKICK-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- IZUPBVBPLAPZRR-UHFFFAOYSA-N pentachloro-phenol Natural products OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IZUPBVBPLAPZRR-UHFFFAOYSA-N 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 238000005191 phase separation Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000003039 volatile agent Substances 0.000 description 3
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- NOASBJYTBZMVKT-UHFFFAOYSA-N 2-(2-chloropyridin-3-yl)acetic acid Chemical compound OC(=O)CC1=CC=CN=C1Cl NOASBJYTBZMVKT-UHFFFAOYSA-N 0.000 description 2
- DMWOJKQPJYWCCB-UHFFFAOYSA-N 2-(2-chloropyridin-3-yl)acetonitrile Chemical compound ClC1=NC=CC=C1CC#N DMWOJKQPJYWCCB-UHFFFAOYSA-N 0.000 description 2
- QWIIJVGEBIQHSW-UHFFFAOYSA-N 2-chloro-3-(chloromethyl)pyridine Chemical compound ClCC1=CC=CN=C1Cl QWIIJVGEBIQHSW-UHFFFAOYSA-N 0.000 description 2
- 0 Cc(nccc1)c1C(*)=C(Nc1ccc(*)cc1*)S Chemical compound Cc(nccc1)c1C(*)=C(Nc1ccc(*)cc1*)S 0.000 description 2
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 101001014196 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 2
- 101001115402 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 2 Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- GMWFCJXSQQHBPI-UHFFFAOYSA-N azetidin-3-ol Chemical compound OC1CNC1 GMWFCJXSQQHBPI-UHFFFAOYSA-N 0.000 description 2
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000004807 desolvation Methods 0.000 description 2
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002148 esters Chemical group 0.000 description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 2
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 102000050156 human MAP2K1 Human genes 0.000 description 2
- 102000050154 human MAP2K2 Human genes 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- XXNGIBYMFXDVAI-UHFFFAOYSA-N (2,3,4,5,6-pentafluorophenyl) 2-(2-fluoro-4-iodoanilino)thieno[2,3-b]pyridine-3-sulfonate Chemical compound FC1=CC(I)=CC=C1NC1=C(S(=O)(=O)OC=2C(=C(F)C(F)=C(F)C=2F)F)C2=CC=CN=C2S1 XXNGIBYMFXDVAI-UHFFFAOYSA-N 0.000 description 1
- HMPDWSBKPCOQDW-UHFFFAOYSA-N (2-chloropyridin-3-yl)methanol Chemical compound OCC1=CC=CN=C1Cl HMPDWSBKPCOQDW-UHFFFAOYSA-N 0.000 description 1
- JHHZLHWJQPUNKB-SCSAIBSYSA-N (3r)-pyrrolidin-3-ol Chemical compound O[C@@H]1CCNC1 JHHZLHWJQPUNKB-SCSAIBSYSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- DFPYXQYWILNVAU-UHFFFAOYSA-N 1-hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1.C1=CC=C2N(O)N=NC2=C1 DFPYXQYWILNVAU-UHFFFAOYSA-N 0.000 description 1
- VNVQCOLTWDGDES-UHFFFAOYSA-N 2-(2-fluoro-4-iodoanilino)thieno[2,3-b]pyridine-3-carboxylic acid Chemical compound S1C2=NC=CC=C2C(C(=O)O)=C1NC1=CC=C(I)C=C1F VNVQCOLTWDGDES-UHFFFAOYSA-N 0.000 description 1
- FUFNKKOFSVIDJW-UHFFFAOYSA-N 2-fluoro-4-iodo-1-isothiocyanatobenzene Chemical compound FC1=CC(I)=CC=C1N=C=S FUFNKKOFSVIDJW-UHFFFAOYSA-N 0.000 description 1
- CUMTUBVTKOYYOU-UHFFFAOYSA-N 2-fluoro-4-iodoaniline Chemical compound NC1=CC=C(I)C=C1F CUMTUBVTKOYYOU-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- XBCHPAKJKIEEJG-UHFFFAOYSA-N 3-(aminomethyl)azetidin-3-ol;2,2,2-trifluoroacetic acid Chemical compound NCC1(O)CNC1.OC(=O)C(F)(F)F XBCHPAKJKIEEJG-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 1
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 241000400611 Eucalyptus deanei Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 101150024075 Mapk1 gene Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- UQUPQEUNHVVNKW-UHFFFAOYSA-N azetidin-1-ium-3-ol;chloride Chemical class Cl.OC1CNC1 UQUPQEUNHVVNKW-UHFFFAOYSA-N 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 238000012822 chemical development Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 229960002152 chlorhexidine acetate Drugs 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000000911 decarboxylating effect Effects 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000003759 ester based solvent Substances 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- VEUUMBGHMNQHGO-UHFFFAOYSA-N ethyl chloroacetate Chemical compound CCOC(=O)CCl VEUUMBGHMNQHGO-UHFFFAOYSA-N 0.000 description 1
- 125000006260 ethylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])C([H])([H])[H] 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000002875 fluorescence polarization Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- NAQDODYLEOKQPD-UHFFFAOYSA-N n-(2-fluoro-4-iodophenyl)thieno[2,3-b]pyridin-2-amine Chemical compound FC1=CC(I)=CC=C1NC1=CC2=CC=CN=C2S1 NAQDODYLEOKQPD-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- PSACHCMMPFMFAJ-UHFFFAOYSA-N nmm n-methylmorpholine Chemical compound CN1CCOCC1.CN1CCOCC1 PSACHCMMPFMFAJ-UHFFFAOYSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000013110 organic ligand Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical class [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- VILMUCRZVVVJCA-UHFFFAOYSA-M sodium glycolate Chemical compound [Na+].OCC([O-])=O VILMUCRZVVVJCA-UHFFFAOYSA-M 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- DUYWGUJDIRKARQ-UHFFFAOYSA-N tert-butyl 3-hydroxy-3-(nitromethyl)azetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(O)(C[N+]([O-])=O)C1 DUYWGUJDIRKARQ-UHFFFAOYSA-N 0.000 description 1
- VMKIXWAFFVLJCK-UHFFFAOYSA-N tert-butyl 3-oxoazetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(=O)C1 VMKIXWAFFVLJCK-UHFFFAOYSA-N 0.000 description 1
- MYUOASAOYLPFTP-UHFFFAOYSA-N tert-butyl 4-[2-(2-fluoro-4-iodoanilino)thieno[2,3-b]pyridin-3-yl]sulfonylpiperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1S(=O)(=O)C(C1=CC=CN=C1S1)=C1NC1=CC=C(I)C=C1F MYUOASAOYLPFTP-UHFFFAOYSA-N 0.000 description 1
- NEMXVXVJGXZDRR-UHFFFAOYSA-N tert-butyl n-(azetidin-3-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1CNC1 NEMXVXVJGXZDRR-UHFFFAOYSA-N 0.000 description 1
- MOLUHRBHXXGWDP-UHFFFAOYSA-N tert-butyl n-(azetidin-3-ylmethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCC1CNC1 MOLUHRBHXXGWDP-UHFFFAOYSA-N 0.000 description 1
- ZCTBUJLBVONGJN-CQSZACIVSA-N tert-butyl n-[(3r)-1-[2-(2-fluoro-4-iodoanilino)thieno[2,3-b]pyridin-3-yl]sulfonylpyrrolidin-3-yl]carbamate Chemical compound C1[C@H](NC(=O)OC(C)(C)C)CCN1S(=O)(=O)C(C1=CC=CN=C1S1)=C1NC1=CC=C(I)C=C1F ZCTBUJLBVONGJN-CQSZACIVSA-N 0.000 description 1
- GXXXZFXHSUDKNG-UHFFFAOYSA-N tert-butyl n-[[1-[2-(2-fluoro-4-iodoanilino)thieno[2,3-b]pyridin-3-yl]sulfonylazetidin-3-yl]methyl]carbamate Chemical compound C1C(CNC(=O)OC(C)(C)C)CN1S(=O)(=O)C(C1=CC=CN=C1S1)=C1NC1=CC=C(I)C=C1F GXXXZFXHSUDKNG-UHFFFAOYSA-N 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- MHXBHWLGRWOABW-UHFFFAOYSA-N tetradecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC MHXBHWLGRWOABW-UHFFFAOYSA-N 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the present invention relates to a class of thieno-pyridine derivatives and to their use in therapy. More particularly, the invention is concerned with thieno[2,3- b ]pyridine derivatives which are substituted in the 2-position by a substituted anilino moiety.
- MAPKK MEK
- These compounds are selective inhibitors of MEK (MAPKK) enzymes, and are accordingly of benefit as pharmaceutical agents, especially in the treatment of adverse inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions.
- MEK enzymes are implicated in a variety of physiological and pathological functions that are believed to be operative in a range of human diseases. These functions are summarised in paragraphs [0004] and [0005] of US 2005/0049276 A1 .
- the compounds of use in the present invention are therefore beneficial in the treatment and/or prevention of various human ailments.
- autoimmune and inflammatory disorders such as rheumatoid arthritis, osteoarthritis, multiple sclerosis, asthma, inflammatory bowel disease, psoriasis and transplant rejection; cardiovascular disorders including thrombosis, cardiac hypertrophy, hypertension, and irregular contractility of the heart (e.g.
- proliferative disorders such as restenosis, and oncological conditions including leukaemia, glioblastoma, lymphoma, melanoma, and human cancers of the liver, bone, skin, brain, pancreas, lung, breast, stomach, colon, rectum, prostate, ovary and cervix; and pain and nociceptive disorders, including chronic pain and neuropathic pain.
- the compounds of use in the present invention may be beneficial as pharmacological standards for use in the development of new biological tests and in the search for new pharmacological agents.
- the compounds of use in this invention may be useful as radioligands in assays for detecting compounds capable of binding to human MEK enzymes.
- MEK inhibitors based on a fused bicyclic aromatic ring system attached to a substituted anilino moiety are known from the art. Examples of relevant publications include WO 2005/051906 , WO 2005/023251 , US-A-2005/0049276 , WO 2005/009975 , WO 03/077914 and WO 03/077855 .
- WO 2005/023818 describes a broad-ranging class of compounds based on a fused bicyclic aromatic ring system, which generically encompasses thieno-pyridine derivatives attached to a substituted anilino moiety but nowhere specifically discloses any precise compound of this type. No discrete pharmacological activity, in terms of an identifiable pharmacological mechanism, is ascribed to the compounds described therein, but they are nevertheless stated to be useful inter alia in the treatment of cell proliferative diseases such as cancer. US-A-2003/0220365 is also of relevance in a related context.
- the compounds of the present invention are potent and selective MEK inhibitors having a binding affinity (IC 50 ) for the human MEK1 and/or MEK2 enzyme of 50 ⁇ M or less, generally of 20 ⁇ M or less, usually of 5 ⁇ M or less, typically of 1 ⁇ M or less, suitably of 500 nM or less, ideally of 100 nM or less, and preferably of 20 nM or less (the skilled person will appreciate that a lower IC 50 figure denotes a more active compound).
- IC 50 binding affinity for the human MEK1 and/or MEK2 enzyme of 50 ⁇ M or less, generally of 20 ⁇ M or less, usually of 5 ⁇ M or less, typically of 1 ⁇ M or less, suitably of 500 nM or less, ideally of 100 nM or less, and preferably of 20 nM or less (the skilled person will appreciate that a lower IC 50 figure denotes a more active compound).
- the compounds of the invention may possess at least a 10-fold selective affinity, typically at least a 20-fold selective affinity, suitably at least a 50-fold selective affinity, and ideally at least a 100-fold selective affinity, for the human MEK1 and/or MEK2 enzyme relative to other human kinases.
- the present invention provides a compound of formula (1), or a pharmaceutically acceptable salt, solvate or N -oxide thereof: wherein
- the salts of the compounds of formula (I) will be pharmaceutically acceptable salts.
- Other salts may, however, be useful in the preparation of the compounds of the invention or of their pharmaceutically acceptable salts.
- Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound of the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, methanesulphonic acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid or phosphoric acid.
- a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, methanesulphonic acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid or phosphoric acid.
- the compounds of the invention carry an acidic moiety, e.g.
- suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g. sodium or potassium salts; alkaline earth metal salts, e.g. calcium or magnesium salts; and salts formed with suitable organic ligands, e.g. quaternary ammonium salts.
- alkali metal salts e.g. sodium or potassium salts
- alkaline earth metal salts e.g. calcium or magnesium salts
- suitable organic ligands e.g. quaternary ammonium salts.
- solvates of the compounds of formula (I) above include within its scope solvates of the compounds of formula (I) above.
- Such solvates may be formed with common organic solvents, e.g. hydrocarbon solvents such as benzene or toluene; chlorinated solvents such as chloroform or dichloromethane; alcoholic solvents such as methanol, ethanol or isopropanol; ethereal solvents such as diethyl ether or tetrahydrofuran; or ester solvents such as ethyl acetate.
- the solvates of the compounds of formula (I) may be formed with water, in which case they will be hydrates.
- Suitable alkyl groups which may be present on the compounds of the invention include straight-chained and branched C 1-6 alkyl groups, for example C 1-4 alkyl groups. Typical examples include methyl and ethyl groups, and straight-chained or branched propyl, butyl and pentyl groups. Particular alkyl groups include methyl, ethyl, n-propyl, isopropyl, n -butyl, sec -butyl, isobutyl, tert -butyl and 2,2-dimethylpropyl. Derived expressions such as "C 1-6 alkoxy" and "C 1-6 alkylamino" are to be construed accordingly.
- halogen as used herein is intended to include fluorine, chlorine, bromine and iodine atoms.
- the compounds of formula (I) may accordingly exist as enantiomers. Where the compounds of the invention possess two or more asymmetric centres, they may additionally exist as diastereomers. The invention is to be understood to extend to all such enantiomers and diastereomers, and to mixtures thereof in any proportion, including racemates.
- Formula (I) and the formulae depicted hereinafter are intended to represent all individual stereoisomers and all possible mixtures thereof, unless stated or shown otherwise.
- Formula (I) and the formulae depicted hereinafter are intended to represent all individual tautomers and all possible mixtures thereof, unless stated or shown otherwise.
- R 1 represents hydrogen. In another embodiment, R 1 represents halogen, particularly fluoro or chloro, especially fluoro. In a further embodiment, R 1 represents C 1-6 alkyl, especially methyl.
- R 1 is fluoro
- R 2 represents halogen, especially bromo or iodo. In another embodiment, R 2 represents C 1-6 alkyl, especially methyl.
- R 2 is bromo. In another specific embodiment, R 2 is iodo.
- the cyclic moiety -NR b R c may be unsubstituted, or substituted by one or more substituents, typically by one or two substituents.
- the cyclic moiety -NR b R c is unsubstituted.
- the cyclic moiety -NR b R c is monosubstituted.
- the cyclic moiety -NR b R c is disubstituted.
- Examples of particular substituents on the cyclic moiety -NR b R c include methyl, hydroxy, hydroxymethyl, 2-hydroxyethyl, methoxy, methoxymethyl, aminomethyl, 2-amino-3-hydroxypropyl, fluoro, oxo, acetyl, carboxy, carboxymethyl, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, ethoxycarbonylmethyl, dimethylhydrazinyl-carbonyl, amino, methylamino, 1,3-dimethylbutylamino, dimethylamino, acetylamino, tert-butoxycarbonylamino, tert-butoxycarbonylaminomethyl, ethoxycarbonylmethylaminomethyl, ethoxycarbonylethylaminomethyl, aminocarbonylamino, aminocarbonyl, ethylaminocarbonyl, diethylaminocarbonyl, aminosulfon
- favoured substituents on the cyclic moiety -NR b R c include hydroxy, amino, amino(C 1-6 )alkyl, C 2-6 alkoxycarbonylamino and C 2-6 alkoxycarbonyl(C 1-6 )alkylamino(C 1-6 )alkyl.
- Examples of specific substituents on the cyclic moiety -NR b R c include hydroxy, amino, aminomethyl, tert-butoxycarbonylamino, ethoxycarbonylmethylaminomethyl and ethoxycarbonylethylaminomethyl.
- cyclic moiety -NR b R c include azetidin-1-yl, pyrrolidin-1-yl and piperazin-1-yl, any of which groups may be optionally substituted by one or more substituents.
- Specific values of the cyclic moiety -NR b R c include 3-hydroxyazetidin-1-yl, 3-aminoazetidin-1-yl, 3-(aminomethyl)azetidin-1-yl, 3-(aminomethyl)-3-hydroxyazetidin-1-yl, 3-( tert -butoxycarbonylamino)azetidin-1-yl, 3-(ethoxycarbonylmethylaminomethyl)-azetidin-1-yl, 3-(ethoxycarbonylethylaminomethyl)azetidin-1-yl, pyrrolidin-1-yl, 3-hydroxypyrrolidin-1-yl, 3-aminopyrrolidin-1-yl, 3-( tert -butoxycarbonylamino)pyrrolidin-1-yl and piperazin-1-yl.
- a particular sub-group of compounds according to the invention is represented by the compounds of formula (II), and pharmaceutically acceptable salts, solvates and N-oxides thereof: wherein R 12 represents halogen; and R 3 is as defined above.
- R 12 is bromo. In another specific embodiment, R 12 is iodo.
- the present invention also provides a pharmaceutical composition which comprises a compound of formula (I) as defined above, or a pharmaceutically acceptable salt, solvate or N -oxide thereof, in association with one or more pharmaceutically acceptable carriers.
- compositions according to the invention may take a form suitable for oral, buccal, parenteral, nasal, topical, ophthalmic or rectal administration, or a form suitable for administration by inhalation or insufflation.
- the pharmaceutical compositions may take the form of, for example, tablets, lozenges or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methyl cellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogenphosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium glycollate); or wetting agents (e.g. sodium lauryl sulphate).
- binding agents e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methyl cellulose
- fillers e.g. lactose, microcrystalline cellulose or calcium hydrogenphosphate
- lubricants e.g. magnesium stearate, talc or silica
- disintegrants e.g. potato starch or sodium glycollate
- Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use.
- Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents, emulsifying agents, non-aqueous vehicles or preservatives.
- the preparations may also contain buffer salts, flavouring agents, colouring agents or sweetening agents, as appropriate.
- Preparations for oral administration may be suitably formulated to give controlled release of the active compound.
- compositions may take the form of tablets or lozenges formulated in conventional manner.
- the compounds of formula (I) may be formulated for parenteral administration by injection, e.g. by bolus injection or infusion.
- Formulations for injection may be presented in unit dosage form, e.g. in glass ampoules or multi-dose containers, e.g. glass vials.
- the compositions for injection may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising, preserving and/or dispersing agents.
- the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.
- the compounds of formula (I) may also be formulated as a depot preparation. Such long-acting formulations may be administered by implantation or by intramuscular injection.
- the compounds according to the present invention may be conveniently delivered in the form of an aerosol spray presentation for pressurised packs or a nebuliser, with the use of a suitable propellant, e.g. dichlorodifluoromethane, fluorotrichloromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas or mixture of gases.
- a suitable propellant e.g. dichlorodifluoromethane, fluorotrichloromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas or mixture of gases.
- compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient.
- the pack or dispensing device may be accompanied by instructions for administration.
- the compounds according to the present invention may be conveniently formulated in a suitable ointment containing the active component suspended or dissolved in one or more pharmaceutically acceptable carriers.
- Particular carriers include, for example, mineral oil, liquid petroleum, propylene glycol, polyoxyethylene, polyoxypropylene, emulsifying wax and water.
- the compounds according to the present invention may be formulated in a suitable lotion containing the active component suspended or dissolved in one or more pharmaceutically acceptable carriers.
- Particular carriers include, for example, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, benzyl alcohol, 2-octyldodecanol and water.
- the compounds according to the present invention may be conveniently formulated as microionized suspensions in isotonic, pH-adjusted sterile saline, either with or without a preservative such as a bactericidal or fungicidal agent, for example phenylmercuric nitrate, benzylalkonium chloride or chlorhexidine acetate.
- a preservative such as a bactericidal or fungicidal agent, for example phenylmercuric nitrate, benzylalkonium chloride or chlorhexidine acetate.
- compounds may be formulated in an ointment such as petrolatum.
- the compounds according to the present invention may be conveniently formulated as suppositories. These can be prepared by mixing the active component with a suitable non-irritating excipient which is solid at room temperature but liquid at rectal temperature and so will melt in the rectum to release the active component.
- suitable non-irritating excipient include, for example, cocoa butter, beeswax and polyethylene glycols.
- daily dosages may range from around 10 ng/kg to 1000 mg/kg, typically from 100 ng/kg to 100 mg/kg, e.g. around 0.01 mg/kg to 40 mg/kg body weight, for oral or buccal administration, from around 10 ng/kg to 50 mg/kg body weight for parenteral administration, and from around 0.05 mg to around 1000 mg, e.g. from around 0.5 mg to around 1000 mg, for nasal administration or administration by inhalation or insufflation.
- R 3 represents -SO 2 NR b R c
- R 3 represents -SO 2 NR b R c
- R 1 and R 2 are as defined above.
- reaction is conveniently effected in a suitable solvent, e.g. dichloromethane, typically under basic conditions, e.g. in the presence of an organic base such as pyridine or triethylamine.
- a suitable solvent e.g. dichloromethane
- organic base such as pyridine or triethylamine.
- the intermediates of formula (III) may suitably be prepared by reacting a compound of formula (IV): wherein R 1 and R 2 are as defined above; with chlorosulphonic acid; followed by treatment with pentafluorophenol, typically in the presence of an organic base such as pyridine.
- the compounds of formula (I) above wherein R 3 represents -SO 2 NR b R c may be prepared by a process which comprises reacting a compound of formula (IV) as defined above with chlorosulphonic acid; followed by treatment with a compound of formula H-NR b R c .
- the reaction is conveniently effected in an inert solvent, e.g. dichloromethane.
- the intermediates of formula (IV) may suitably be prepared by decarboxylating a compound of formula (V): wherein R 1 and R 2 are as defined above.
- Decarboxylation is conveniently effected by heating compound (V), typically at the reflux temperature, in an inert solvent such as toluene.
- the intermediates of formula (V) above may suitably be prepared by reacting a compound of formula (VI) with a compound of formula (VII): wherein R 1 and R 2 are as defined above, and L 1 represents a suitable leaving group.
- the leaving group L 1 is typically a halogen atom, e.g. chloro.
- reaction is conveniently effected, at an elevated temperature if necessary, in a suitable solvent, e.g. tetrahydrofuran, typically under basic conditions, e.g. in the presence of lithium diisopropylamide.
- a suitable solvent e.g. tetrahydrofuran
- basic conditions e.g. in the presence of lithium diisopropylamide.
- the intermediates of formula (VII) above may be prepared by reacting a compound of formula (VIII): wherein R 1 and R 2 are as defined above; with thiophosgene.
- reaction is conveniently effected in a suitable solvent, typically a mixture of chloroform and water.
- any compound of formula (I) initially obtained from any of the above processes may, where appropriate, subsequently be elaborated into a further compound of formula (I) by techniques known from the art.
- a compound of formula (I) wherein R 3 contains a nitrogen atom to which a tert -butoxycarbonyl (BOC) group is attached may be converted into the corresponding compound wherein R 3 contains an N-H functionality by treatment with an acid, e.g. a mineral acid such as hydrochloric acid, or an organic acid such as trifluoroacetic acid.
- an acid e.g. a mineral acid such as hydrochloric acid, or an organic acid such as trifluoroacetic acid.
- a compound of formula (I) wherein R 3 contains a nitrogen atom to which a benzyloxycarbonyl group is attached may be converted into the corresponding compound wherein R 3 contains an N-H functionality by treatment with trifluoroacetic acid.
- a compound of formula (I) wherein R 2 contains an N-H functionality may be converted into the corresponding compound wherein R 3 contains a nitrogen atom to which an ethoxycarbonylmethyl group is attached by treatment with ethyl chloroacetate or ethyl bromoacetate, typically in the presence of an organic base such as triethylamine or N,N -diisopropylethylamine; the resulting compound may then be converted into the corresponding compound wherein R 3 contains a nitrogen atom to which a carboxymethyl group is attached by treatment with an alkaline reagent such as sodium hydroxide, typically in an aqueous solution of a lower alkanol such as ethanol.
- an alkaline reagent such as sodium hydro
- a compound of formula (I) wherein R 3 contains an N-H functionality may be converted into the corresponding compound wherein R 3 contains a nitrogen atom to which an ethoxycarbonylethyl group is attached by treatment with ethyl acrylate, typically in the presence of an organic base such as N,N -diisopropylethylamine.
- a compound of formula (I) wherein R 3 contains an ester moiety e.g. a C 1-6 alkoxycarbonyl group such as methoxycarbonyl or ethoxycarbonyl, may be converted into the corresponding compound wherein R 3 contains a carboxy (-CO 2 H moiety by treatment with an alkali metal hydroxide, e.g.
- a compound of formula (I) wherein R 3 contains a 2,2-dimethyl-[1,3]dioxolan-4-ylmethyl moiety may be converted into the corresponding compound wherein R 3 contains a 2,3-dihydroxypropyl moiety by treatment with a mineral acid such as hydrochloric acid.
- the pyridine- N -oxide derivative of a compound of formula (I) may be converted into the corresponding compound of formula (I) by treatment with triphenyl phosphine and phosphorus trichloride.
- the desired product can be separated therefrom at an appropriate stage by conventional methods such as preparative HPLC; or column chromatography utilising, for example, silica and/or alumina in conjunction with an appropriate solvent system.
- the diastereomers may then be separated by any convenient means, for example by crystallisation, and the desired enantiomer recovered, e.g. by treatment with an acid in the instance where the diastereomer is a salt.
- a racemate of formula (I) may be separated using chiral HPLC.
- a particular enantiomer may be obtained by using an appropriate chiral intermediate in one of the processes described above.
- a particular enantiomer may be obtained by performing an enantiomer-specific enzymatic biotransformation, e.g. an ester hydrolysis using an esterase, and then purifying only the enantiomerically pure hydrolysed acid from the unreacted ester antipode. Chromatography, recrystallisation and other conventional separation procedures may also be used with intermediates or final products where it is desired to obtain a particular geometric isomer of the invention.
- any of the above synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973 ; and T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Syntheses, John Wiley & Sons, 3rd edition, 1999 .
- the protecting groups may be removed at any convenient subsequent stage utilising methods known from the art.
- the compounds in accordance with this invention potently inhibit the activity of human MEK enzyme.
- MEK1 activity was measured in a cascade assay initiated by active Raf, via activation of MEK, Erk2 and subsequent phosphorylation of fluorescein-labelled Erk-tide substrate in an assay based on fluorescence polarisation (IMAP).
- the assay was carried out in 20m M Tris + 5m M MgCl 2 + 2mM DL-dithiothreitol + 0.01 % Tween 20 pH 7.2, containing 1.5n M unactive MEK, 100n M unactive Erk and 200n M Erk-tide (all concentrations are final concentrations).
- the LC-MS system used comprises a Waters Alliance 2795 HT quaternary HPLC, Waters 996 Photo Diode Array (PDA) detector and Waters ZQ 4000 single quadrupole mass spectrometer.
- the ZQ can acquire data simultaneously in positive and negative electrospray ionisation modes.
- the LC system comprises a Waters 2525 quaternary pump, a Waters 996 Photo Diode Array (PDA) detector, a Waters 2700 sample manager, a Column Fluidics Organiser and a Waters Fraction Collector operating in reverse phase at one of two pH systems.
- PDA Waters 996 Photo Diode Array
- Example 3 (300 mg, 0.48 mmol) was treated with a 20% solution of TFA in DCM (5 mL). The reaction mixture was stirred for three hours at room temperature before being diluted with DCM (25 mL) and washed with NaHCO 3 solution (25 mL) and water (25 mL). The organic layer was dried (Na 2 SO 4 ) and evaporated in vacuo to give the title compound as an off-white powder (230 mg, 92%).
- Example 5 (132 mg, 0.21 mmol) was treated with a 20% solution of TFA in DCM (5 mL). The reaction mixture was stirred for three hours at room temperature before being diluted with DCM (25 mL) and washed with saturated aqueous NaHCO 3 solution (25 mL) and water (25mL). The organic layer was dried (Na 2 SO 4 ) and evaporated in vacuo to give the title compound as an off-white powder (66 mg, 61 %).
- Example 2 To a stirring mixture of Example 2 (160 mg, 0.31 mmol) and N,N -diisopropylethylamine (57 ⁇ L, 31 mmol) in DMF (5 mL) was added ethyl acrylate (51 ⁇ L, 0.31 mmol) and the mixture allowed to stir for 18 hours. After this time EtOAc (25 mL) was added to the reaction mixture which was then washed with brine (3 x 25 mL), dried (sodium sulfate) and then reduced in vacuo. The resulting oil was purified by column chromatography (SiO 2 , 50% DCM in EtOAc) to afford the title compound as a colourless oil (71 mg, 38%).
- Example 2 To a stirring mixture of Example 2 (200 mg, 0.39 mmol) and N,N -diisopropyl-ethylamine (68 ⁇ L, 42 mmol) in DMF (5 mL) was added ethyl bromoacetate (43 ⁇ L, 0.39 mmol) and the mixture allowed to stir for 18 hours. After this time EtOAc (25 mL) was added to the reaction mixture which was then washed with brine (3 x 25 mL), dried (sodium sulfate) and then reduced in vacuo. The resulting oil was purified by column chromatography (SiO 2 , 50% DCM in EtOAc) to afford the title compound as a white solid (47 mg, 20%). LCMS (pH 3) RT 2.24 minutes, (ES + ) 605 (M+H).
- Example 15 (125 mg, 0.21 mmol) was dissolved in dichloromethane (3 mL). TFA (2 mL) was added and the reaction mixture was stirred at r.t. for 5 hours. After concentrating in vacuo, the residue was partitioned between ethyl acetate (100 mL) and sat. sodium carbonate solution (100 mL). The organic phase was dried (Na 2 SO 4 ), and concentrated in vacuo to give the title compound as an off-white solid (65 mg, 63%).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
- The present invention relates to a class of thieno-pyridine derivatives and to their use in therapy. More particularly, the invention is concerned with thieno[2,3-b]pyridine derivatives which are substituted in the 2-position by a substituted anilino moiety. These compounds are selective inhibitors of MEK (MAPKK) enzymes, and are accordingly of benefit as pharmaceutical agents, especially in the treatment of adverse inflammatory, autoimmune, cardiovascular, proliferative (including oncological) and nociceptive conditions.
- MEK enzymes are implicated in a variety of physiological and pathological functions that are believed to be operative in a range of human diseases. These functions are summarised in paragraphs [0004] and [0005] of
US 2005/0049276 A1 . - The compounds of use in the present invention, being potent and selective MEK inhibitors, are therefore beneficial in the treatment and/or prevention of various human ailments. These include autoimmune and inflammatory disorders such as rheumatoid arthritis, osteoarthritis, multiple sclerosis, asthma, inflammatory bowel disease, psoriasis and transplant rejection; cardiovascular disorders including thrombosis, cardiac hypertrophy, hypertension, and irregular contractility of the heart (e.g. during heart failure); proliferative disorders such as restenosis, and oncological conditions including leukaemia, glioblastoma, lymphoma, melanoma, and human cancers of the liver, bone, skin, brain, pancreas, lung, breast, stomach, colon, rectum, prostate, ovary and cervix; and pain and nociceptive disorders, including chronic pain and neuropathic pain.
- In addition, the compounds of use in the present invention may be beneficial as pharmacological standards for use in the development of new biological tests and in the search for new pharmacological agents. Thus, the compounds of use in this invention may be useful as radioligands in assays for detecting compounds capable of binding to human MEK enzymes.
- MEK inhibitors based on a fused bicyclic aromatic ring system attached to a substituted anilino moiety are known from the art. Examples of relevant publications include
WO 2005/051906 ,WO 2005/023251 ,US-A-2005/0049276 ,WO 2005/009975 ,WO 03/077914 WO 03/077855 -
WO 2005/023818 describes a broad-ranging class of compounds based on a fused bicyclic aromatic ring system, which generically encompasses thieno-pyridine derivatives attached to a substituted anilino moiety but nowhere specifically discloses any precise compound of this type. No discrete pharmacological activity, in terms of an identifiable pharmacological mechanism, is ascribed to the compounds described therein, but they are nevertheless stated to be useful inter alia in the treatment of cell proliferative diseases such as cancer.US-A-2003/0220365 is also of relevance in a related context. - Nowhere in the prior art publications acknowledged above, however, is there the precise disclosure of a class of thieno[2,3-b]pyridine derivatives attached at the 2-position to a substituted anilino moiety. It has now been found that such compounds are particularly valuable as selective inhibitors of MEK enzymes.
- The compounds of the present invention are potent and selective MEK inhibitors having a binding affinity (IC50) for the human MEK1 and/or MEK2 enzyme of 50 µM or less, generally of 20 µM or less, usually of 5 µM or less, typically of 1 µM or less, suitably of 500 nM or less, ideally of 100 nM or less, and preferably of 20 nM or less (the skilled person will appreciate that a lower IC50 figure denotes a more active compound). The compounds of the invention may possess at least a 10-fold selective affinity, typically at least a 20-fold selective affinity, suitably at least a 50-fold selective affinity, and ideally at least a 100-fold selective affinity, for the human MEK1 and/or MEK2 enzyme relative to other human kinases.
-
- R1 represents hydrogen, halogen or C1-6 alkyl;
- R2 represents halogen or C1-6 alkyl;
- R3 represents -SO2NRbRc; and
- Rb and Rc, when taken together with the nitrogen atom to which they are both attached, represent azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, thiomorpholin-4-yl, piperazin-1-yl, homopiperidin-1-yl, homomorpholin-4-yl or homopiperazin-1-yl, any of which groups may be optionally substituted by one or more substituents selected from C1-6 alkyl, hydroxy, hydroxy(C1-6)alkyl, C1-6 alkoxy, C1-6 alkoxy(C1-6)alkyl, amino(C1-6)alkyl, (amino)(hydroxy)(C1-6)alkyl, halogen, oxo, C2-6 alkylcarbonyl, carboxy, carboxy(C1-6)alkyl, C2-6 alkoxycarbonyl, C2-6 alkoxycarbonyl-(C1-6)alkyl, di(C1-6)alkylhydrazinylcarbonyl, amino, C1-6 alkylamino, di(C1-6)alkylamino, C2-6 alkylcarbonylamino, C2-6 alkoxycarbonylamino, C2-6 alkoxycarbonylamino(C1-6)-alkyl, C2-6 alkoxycarbonyl(C1-6)alkylamino(C1-6)alkyl, aminocarbonylamino, aminocarbonyl, C1-6 alkylaminocarbonyl, di(C1-6)alkylaminocarbonyl, aminosulfonyl, C1-6 alkylsulfonyl and C1-6 alkylaminocarbonyl(C1-6)alkyl.
- Co-pending international patent application no.
PCT/GB2007/000310, published on 9 August 2007 WO 2007/088345 , describes a class of compounds of formula (I) as depicted above, and pharmaceutically acceptable salts, solvates and N-oxides thereof, as MEK inhibitors. Substituent R3 as defined therein, however, differs in all respects from substituent R3 as defined above. - For use in medicine, the salts of the compounds of formula (I) will be pharmaceutically acceptable salts. Other salts may, however, be useful in the preparation of the compounds of the invention or of their pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound of the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, methanesulphonic acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid or phosphoric acid. Furthermore, where the compounds of the invention carry an acidic moiety, e.g. carboxy, suitable pharmaceutically acceptable salts thereof may include alkali metal salts, e.g. sodium or potassium salts; alkaline earth metal salts, e.g. calcium or magnesium salts; and salts formed with suitable organic ligands, e.g. quaternary ammonium salts.
- The present invention includes within its scope solvates of the compounds of formula (I) above. Such solvates may be formed with common organic solvents, e.g. hydrocarbon solvents such as benzene or toluene; chlorinated solvents such as chloroform or dichloromethane; alcoholic solvents such as methanol, ethanol or isopropanol; ethereal solvents such as diethyl ether or tetrahydrofuran; or ester solvents such as ethyl acetate. Alternatively, the solvates of the compounds of formula (I) may be formed with water, in which case they will be hydrates.
- Suitable alkyl groups which may be present on the compounds of the invention include straight-chained and branched C1-6 alkyl groups, for example C1-4 alkyl groups. Typical examples include methyl and ethyl groups, and straight-chained or branched propyl, butyl and pentyl groups. Particular alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl and 2,2-dimethylpropyl. Derived expressions such as "C1-6 alkoxy" and "C1-6 alkylamino" are to be construed accordingly.
- The term "halogen" as used herein is intended to include fluorine, chlorine, bromine and iodine atoms.
- Where the compounds of formula (I) have one or more asymmetric centres, they may accordingly exist as enantiomers. Where the compounds of the invention possess two or more asymmetric centres, they may additionally exist as diastereomers. The invention is to be understood to extend to all such enantiomers and diastereomers, and to mixtures thereof in any proportion, including racemates. Formula (I) and the formulae depicted hereinafter are intended to represent all individual stereoisomers and all possible mixtures thereof, unless stated or shown otherwise. In addition, compounds of formula (I) may exist as tautomers, for example keto (CH2C=O)-enol (CH=CHOH) tautomers. Formula (I) and the formulae depicted hereinafter are intended to represent all individual tautomers and all possible mixtures thereof, unless stated or shown otherwise.
- In one embodiment, R1 represents hydrogen. In another embodiment, R1 represents halogen, particularly fluoro or chloro, especially fluoro. In a further embodiment, R1 represents C1-6 alkyl, especially methyl.
- Typically, R1 is fluoro.
- In one embodiment, R2 represents halogen, especially bromo or iodo. In another embodiment, R2 represents C1-6 alkyl, especially methyl.
- In one specific embodiment, R2 is bromo. In another specific embodiment, R2 is iodo.
- Suitably, the cyclic moiety -NRbRc may be unsubstituted, or substituted by one or more substituents, typically by one or two substituents. In one embodiment, the cyclic moiety -NRbRc is unsubstituted. In another embodiment, the cyclic moiety -NRbRc is monosubstituted. In a further embodiment, the cyclic moiety -NRbRc is disubstituted.
- Examples of particular substituents on the cyclic moiety -NRbRc include methyl, hydroxy, hydroxymethyl, 2-hydroxyethyl, methoxy, methoxymethyl, aminomethyl, 2-amino-3-hydroxypropyl, fluoro, oxo, acetyl, carboxy, carboxymethyl, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, ethoxycarbonylmethyl, dimethylhydrazinyl-carbonyl, amino, methylamino, 1,3-dimethylbutylamino, dimethylamino, acetylamino, tert-butoxycarbonylamino, tert-butoxycarbonylaminomethyl, ethoxycarbonylmethylaminomethyl, ethoxycarbonylethylaminomethyl, aminocarbonylamino, aminocarbonyl, ethylaminocarbonyl, diethylaminocarbonyl, aminosulfonyl, methylsulfonyl and methylaminocarbonylmethyl.
- Examples of favoured substituents on the cyclic moiety -NRbRc include hydroxy, amino, amino(C1-6)alkyl, C2-6 alkoxycarbonylamino and C2-6 alkoxycarbonyl(C1-6)alkylamino(C1-6)alkyl.
- Examples of specific substituents on the cyclic moiety -NRbRc include hydroxy, amino, aminomethyl, tert-butoxycarbonylamino, ethoxycarbonylmethylaminomethyl and ethoxycarbonylethylaminomethyl.
- Particular values for the cyclic moiety -NRbRc include azetidin-1-yl, pyrrolidin-1-yl and piperazin-1-yl, any of which groups may be optionally substituted by one or more substituents.
- Specific values of the cyclic moiety -NRbRc include 3-hydroxyazetidin-1-yl, 3-aminoazetidin-1-yl, 3-(aminomethyl)azetidin-1-yl, 3-(aminomethyl)-3-hydroxyazetidin-1-yl, 3-(tert-butoxycarbonylamino)azetidin-1-yl, 3-(ethoxycarbonylmethylaminomethyl)-azetidin-1-yl, 3-(ethoxycarbonylethylaminomethyl)azetidin-1-yl, pyrrolidin-1-yl, 3-hydroxypyrrolidin-1-yl, 3-aminopyrrolidin-1-yl, 3-(tert-butoxycarbonylamino)pyrrolidin-1-yl and piperazin-1-yl.
-
- In one specific embodiment, R12 is bromo. In another specific embodiment, R12 is iodo.
- Specific novel compounds in accordance with the present invention include each of the compounds whose preparation is described in the accompanying Examples, and pharmaceutically acceptable salts and solvates thereof.
- The present invention also provides a pharmaceutical composition which comprises a compound of formula (I) as defined above, or a pharmaceutically acceptable salt, solvate or N-oxide thereof, in association with one or more pharmaceutically acceptable carriers.
- Pharmaceutical compositions according to the invention may take a form suitable for oral, buccal, parenteral, nasal, topical, ophthalmic or rectal administration, or a form suitable for administration by inhalation or insufflation.
- For oral administration, the pharmaceutical compositions may take the form of, for example, tablets, lozenges or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methyl cellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogenphosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium glycollate); or wetting agents (e.g. sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents, emulsifying agents, non-aqueous vehicles or preservatives. The preparations may also contain buffer salts, flavouring agents, colouring agents or sweetening agents, as appropriate.
- Preparations for oral administration may be suitably formulated to give controlled release of the active compound.
- For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.
- The compounds of formula (I) may be formulated for parenteral administration by injection, e.g. by bolus injection or infusion. Formulations for injection may be presented in unit dosage form, e.g. in glass ampoules or multi-dose containers, e.g. glass vials. The compositions for injection may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising, preserving and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.
- In addition to the formulations described above, the compounds of formula (I) may also be formulated as a depot preparation. Such long-acting formulations may be administered by implantation or by intramuscular injection.
- For nasal administration or administration by inhalation, the compounds according to the present invention may be conveniently delivered in the form of an aerosol spray presentation for pressurised packs or a nebuliser, with the use of a suitable propellant, e.g. dichlorodifluoromethane, fluorotrichloromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas or mixture of gases.
- The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack or dispensing device may be accompanied by instructions for administration.
- For topical administration the compounds according to the present invention may be conveniently formulated in a suitable ointment containing the active component suspended or dissolved in one or more pharmaceutically acceptable carriers. Particular carriers include, for example, mineral oil, liquid petroleum, propylene glycol, polyoxyethylene, polyoxypropylene, emulsifying wax and water. Alternatively, the compounds according to the present invention may be formulated in a suitable lotion containing the active component suspended or dissolved in one or more pharmaceutically acceptable carriers. Particular carriers include, for example, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, benzyl alcohol, 2-octyldodecanol and water.
- For ophthalmic administration the compounds according to the present invention may be conveniently formulated as microionized suspensions in isotonic, pH-adjusted sterile saline, either with or without a preservative such as a bactericidal or fungicidal agent, for example phenylmercuric nitrate, benzylalkonium chloride or chlorhexidine acetate. Alternatively, for ophthalmic administration compounds may be formulated in an ointment such as petrolatum.
- For rectal administration the compounds according to the present invention may be conveniently formulated as suppositories. These can be prepared by mixing the active component with a suitable non-irritating excipient which is solid at room temperature but liquid at rectal temperature and so will melt in the rectum to release the active component. Such materials include, for example, cocoa butter, beeswax and polyethylene glycols.
- The quantity of a compound of the invention required for the prophylaxis or treatment of a particular condition will vary depending on the compound chosen and the condition of the patient to be treated. In general, however, daily dosages may range from around 10 ng/kg to 1000 mg/kg, typically from 100 ng/kg to 100 mg/kg, e.g. around 0.01 mg/kg to 40 mg/kg body weight, for oral or buccal administration, from around 10 ng/kg to 50 mg/kg body weight for parenteral administration, and from around 0.05 mg to around 1000 mg, e.g. from around 0.5 mg to around 1000 mg, for nasal administration or administration by inhalation or insufflation.
-
- The reaction is conveniently effected in a suitable solvent, e.g. dichloromethane, typically under basic conditions, e.g. in the presence of an organic base such as pyridine or triethylamine.
-
- In an alternative procedure, the compounds of formula (I) above wherein R3 represents -SO2NRbRc may be prepared by a process which comprises reacting a compound of formula (IV) as defined above with chlorosulphonic acid; followed by treatment with a compound of formula H-NRbRc. The reaction is conveniently effected in an inert solvent, e.g. dichloromethane.
-
- Decarboxylation is conveniently effected by heating compound (V), typically at the reflux temperature, in an inert solvent such as toluene.
-
- The leaving group L1 is typically a halogen atom, e.g. chloro.
- The reaction is conveniently effected, at an elevated temperature if necessary, in a suitable solvent, e.g. tetrahydrofuran, typically under basic conditions, e.g. in the presence of lithium diisopropylamide.
-
- The reaction is conveniently effected in a suitable solvent, typically a mixture of chloroform and water.
- Where they are not commercially available, the starting materials of formula (VI) and (VIII) may be prepared by methods analogous to those described in the accompanying Examples, or by standard methods well known from the art.
- It will be understood that any compound of formula (I) initially obtained from any of the above processes may, where appropriate, subsequently be elaborated into a further compound of formula (I) by techniques known from the art. By way of example, a compound of formula (I) wherein R3 contains a nitrogen atom to which a tert-butoxycarbonyl (BOC) group is attached may be converted into the corresponding compound wherein R3 contains an N-H functionality by treatment with an acid, e.g. a mineral acid such as hydrochloric acid, or an organic acid such as trifluoroacetic acid. A compound of formula (I) wherein R3 contains a nitrogen atom to which a benzyloxycarbonyl group is attached may be converted into the corresponding compound wherein R3 contains an N-H functionality by treatment with trifluoroacetic acid. A compound of formula (I) wherein R2 contains an N-H functionality may be converted into the corresponding compound wherein R3 contains a nitrogen atom to which an ethoxycarbonylmethyl group is attached by treatment with ethyl chloroacetate or ethyl bromoacetate, typically in the presence of an organic base such as triethylamine or N,N-diisopropylethylamine; the resulting compound may then be converted into the corresponding compound wherein R3 contains a nitrogen atom to which a carboxymethyl group is attached by treatment with an alkaline reagent such as sodium hydroxide, typically in an aqueous solution of a lower alkanol such as ethanol. A compound of formula (I) wherein R3 contains an N-H functionality may be converted into the corresponding compound wherein R3 contains a nitrogen atom to which an ethoxycarbonylethyl group is attached by treatment with ethyl acrylate, typically in the presence of an organic base such as N,N-diisopropylethylamine. In general, a compound of formula (I) wherein R3 contains an ester moiety, e.g. a C1-6 alkoxycarbonyl group such as methoxycarbonyl or ethoxycarbonyl, may be converted into the corresponding compound wherein R3 contains a carboxy (-CO2H moiety by treatment with an alkali metal hydroxide, e.g. sodium hydroxide or lithium hydroxide. A compound of formula (I) wherein R3 contains a 2,2-dimethyl-[1,3]dioxolan-4-ylmethyl moiety may be converted into the corresponding compound wherein R3 contains a 2,3-dihydroxypropyl moiety by treatment with a mineral acid such as hydrochloric acid. The pyridine-N-oxide derivative of a compound of formula (I) may be converted into the corresponding compound of formula (I) by treatment with triphenyl phosphine and phosphorus trichloride.
- Where a mixture of products is obtained from any of the processes described above for the preparation of compounds according to the invention, the desired product can be separated therefrom at an appropriate stage by conventional methods such as preparative HPLC; or column chromatography utilising, for example, silica and/or alumina in conjunction with an appropriate solvent system.
- Where the above-described processes for the preparation of the compounds according to the invention give rise to mixtures of stereoisomers, these isomers may be separated by conventional techniques. In particular, where it is desired to obtain a particular enantiomer of a compound of formula (I) this may be produced from a corresponding mixture of enantiomers using any suitable conventional procedure for resolving enantiomers. Thus, for example, diastereomeric derivatives, e.g. salts, may be produced by reaction of a mixture of enantiomers of formula (I), e.g. a racemate, and an appropriate chiral compound, e.g. a chiral base. The diastereomers may then be separated by any convenient means, for example by crystallisation, and the desired enantiomer recovered, e.g. by treatment with an acid in the instance where the diastereomer is a salt. In another resolution process a racemate of formula (I) may be separated using chiral HPLC. Moreover, if desired, a particular enantiomer may be obtained by using an appropriate chiral intermediate in one of the processes described above. Alternatively, a particular enantiomer may be obtained by performing an enantiomer-specific enzymatic biotransformation, e.g. an ester hydrolysis using an esterase, and then purifying only the enantiomerically pure hydrolysed acid from the unreacted ester antipode. Chromatography, recrystallisation and other conventional separation procedures may also be used with intermediates or final products where it is desired to obtain a particular geometric isomer of the invention.
- During any of the above synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wuts, Protective Groups in Organic Syntheses, John Wiley & Sons, 3rd edition, 1999. The protecting groups may be removed at any convenient subsequent stage utilising methods known from the art.
- The following Examples illustrate the preparation of compounds according to the invention.
- The compounds in accordance with this invention potently inhibit the activity of human MEK enzyme.
- MEK1 activity was measured in a cascade assay initiated by active Raf, via activation of MEK, Erk2 and subsequent phosphorylation of fluorescein-labelled Erk-tide substrate in an assay based on fluorescence polarisation (IMAP). The assay was carried out in 20mM Tris + 5mM MgCl2 + 2mM DL-dithiothreitol + 0.01 % Tween 20 pH 7.2, containing 1.5nM unactive MEK, 100nM unactive Erk and 200nM Erk-tide (all concentrations are final concentrations). Compounds, or DMSO controls, were tested at a final concentration of 2% DMSO, and the assay initiated in the presence of 5µM ATP by addition of 1.25nM active Raf in assay buffer. After 20 min at r.t., stop solution was added followed by IMAP binding beads, the assay mixture was then incubated for 90 min at r.t. (with shaking) and then read on a Molecular Devices LJL HT reader.
- When tested in the above assay, the compounds of the accompanying Examples were all found to inhibit human MEK enzyme with IC50 values of 10 µM or better.
-
EtOAc - ethyl acetate DMSO - dimethylsulphoxide THF - tetrahydrofuran DCM - dichloromethane Et2O/ether - diethyl ether CDCl3 - deuterochloroform MeOH - methanol MeCN - acetonitrile EtOH - ethanol ES - electrospray DMF - N,N-dimethylformamide HOBT - 1-hydroxybenzotriazole SiO2 - silica NMM - N-methylmorpholine h - hour(s) min - minute(s) r.t. - room temperature aq - aqueous sat. - saturated RT - retention time conc. - concentrated BOC - tert-butoxycarbonyl TFA - trifluoroacetic acid EDC - 1-(3-dimethylaminopropyl)-3-carbodiimide hydrochloride PyBrOP - (bromo)tris(pyrrolidino)phosphonium hexafluorophosphate Dess-Martin periodinane - 1,1,1-tris(acetyloxy)-1,1-dihydro-1,2-benziodoxol-3(1H)-one - All NMR spectra were obtained either at 300 MHz or 400 MHz.
- Compounds were named with the aid of ACD Labs Name (v. 7.0) supplied by Advanced Chemical Development, Toronto, Canada.
- The LC-MS system used comprises a Waters Alliance 2795 HT quaternary HPLC, Waters 996 Photo Diode Array (PDA) detector and Waters ZQ 4000 single quadrupole mass spectrometer. The ZQ can acquire data simultaneously in positive and negative electrospray ionisation modes.
-
Capillary 3.5kV Cone 50V Extractor 2V Source Temp 80°C Desolvation Temp 200°C Cone Gas 150 L/h Desolvation Gas 250 L/h Multiplier 650V - Data were acquired in a full scan from 100 to 1000 m/z.
Scan duration 0.80 s Interscan delay 0.20 s - Analytical reverse phase separation was carried out on a Gemini C18 from Phenomenex 50 x 4.6 mm with 5 µm silica.
Injection Volume 5 µL UVdata 240 to 400 nm Sample Temperature 20°C Column Temperature 30°C Flow Rate 0.9 mL/min Split to ZQ -0.40 mL/min
Solvent B: 90% CH3CN / 0.1 % formic acid /10% 10mM NH4HCO2 in water
Solvent C: 90% 10mM NH4HCO2 in water /0.1% ammonia / 10% CH3CN
Solvent D: 90% CH3CN /10% 10mM NH4HCO2 in water / 0.1% ammonia - For method 5_95_pH=3
Time (min) A% B% Flow Curve 0.00 95.0 5.0 0.900 1 2.00 5.0 95.0 0.900 6 4.00 5.0 95.0 0.900 6 5.00 95.0 5.0 0.900 6 - For method 5_95_pH=10
Time (min) A% B% Flow Curve 0.00 95.0 5.0 0.900 1 2.00 5.0 95.0 0.900 6 4.00 5.0 95.0 0.900 6 5.00 95.0 5.0 0.900 6 - The LC system comprises a Waters 2525 quaternary pump, a Waters 996 Photo Diode Array (PDA) detector, a Waters 2700 sample manager, a Column Fluidics Organiser and a Waters Fraction Collector operating in reverse phase at one of two pH systems.
- The reverse phase separation was carried out on a Luna C18 from Phenomenex 100 x 21.2 mm with 5 µm silica.
Injection Volume 500 µL UV data 254 nm Flow Rate 20 mL/min Solvent A 90% water / 10% CH3CN / 0.1 % formic acid Solvent B 90% CH3CN / 10% water / 0.1 % formic acid - The reverse phase separation was carried out on a Gemini C18 from Phenomenex 150 x 21.2 mm with 10 µm silica.
Injection Volume 500 µL UV data 254 nm Flow Rate 20 mL/min Solvent C 90% 10mM NH4HCO2 in water / 0.1% ammonia / 10% CH3CN Solvent D 90% CH3CN / 10% 10mM NH4HCO2 in water / 0.1% ammonia - Typical gradient profiles are described below:
-
Time A% B% C% D% Flow Curve 0.00 95.0 5.0 0.0 0.0 20 1 9.00 5.0 95.0 0.0 0.0 20 6 11.00 5.0 95.0 0.0 0.0 20 6 11.50 95.0 5.0 0.0 0.0 20 6 12.00 95.0 5.0 0.0 0.0 20 6 -
Time A% B% C% D% Flow Curve 0.00 0.0 0.0 95.0 5.0 20 1 9.00 0.0 0.0 5.0 95.0 20 6 11.00 0.0 0.0 5.0 95.0 20 6 11.50 0.0 0.0 95.0 5.0 20 6 12.00 0.0 0.0 95.0 5.0 20 6 - To a 500 mL, round-bottom, 3-necked flask equipped with dropping funnel and magnetic stirrer and set for reflux was prepared a solution of 2-chloro-3-(hydroxymethyl)-pyridine (25.0 g, 174 mmol) in DCM (250 mL) under positive nitrogen atmosphere. The solution was cooled to 10°C and thionyl chloride (31.0 g) was added dropwise over 25 minutes (exothermic). The reaction was then heated to reflux for 90 minutes, at which point the reaction was deemed complete by HPLC. The reaction mixture was cooled below boiling point and the equipment set for distillation. A total of 110 mL of DCM was initially removed and replenished with fresh DCM (110 mL), followed by another 80 mL of DCM before cooling the solution to 5-10°C. The acidic mixture was treated with a saturated solution of sodium bicarbonate (3 volumes) to pH 10. The lower organic phase was separated and the aqueous phase extracted with DCM (2 volumes). The organic phases were gathered, dried on sodium sulfate, filtered and concentrated in vacuo to afford the title compound as a pale yellow oil in excellent purity and yield (24.8 g, 88%). δH (d6-DMSO, 300 MHz) 8.45 (1H, dd), 8.10 (1H, dd), 7.50 (1H, dd), 4.85 (2H, s). LCMS (ES)+ RT 3.00 min, m/e 162.1.
- In a 3 L reactor, set for reflux under positive nitrogen pressure and using a bleach scrubber, was prepared a solution of potassium cyanide (68.32 g, 1.04M) in EtOH (136 mL) and water (255 mL). The mixture was heated to reflux, at which point a solution of 2-chloro-3-(chloromethyl)pyridine (Intermediate 1; 170.0 g, 1.04M) in EtOH (170 mL) was added dropwise over 30 minutes. The whole mixture was maintained at reflux for a further 150 minutes. The mixture was then allowed to cool just below boiling point and the equipment set for distillation. A total of 8.5 volumes of EtOH were removed. On cooling, half a volume of water was added. At a temperature of 40°C, the solution was seeded and crystallised instantaneously. The thick beige slurry was allowed to cool to ambient temperature and then to 0°C. This mixture was filtered, rinsed with cold water (2 vols) and dried at 45°C in a vacuum oven overnight. The title compound was afforded as a beige solid in excellent yield and purity (126.9 g, 80%). δH (d6-DMSO, 300 MHz) 8.45 (1H, dd), 8.00 (1H, dd), 7.50 (1H, dd), 4.15 (2H, s). LCMS (ES)+ RT 2.15 min, m/e 153.01 & 155.01 (M+1 & M+3, Product).
- To a 2 L reactor, set for reflux, was stirred a pre-prepared 15% w/w solution of sodium hydroxide (5 vols) to which was added (2-chloropyridin-3-yl)acetonitrile (Intermediate 2; 276.4 g, 1.81M). The beige suspension was heated to reflux for 30 minutes, at which point the reaction was deemed complete by HPLC. The brown solution was then cooled to 0-5°C and acidified to pH 1 with conc. HCl while keeping the temperature below 10°C, using concentrated hydrochloric acid (1.8 vols). An off-white solid precipitated and was left to mature for another hour before filtration. Once dried, the material was recrystallised from propan-2-ol (4 vols) to afford the title compound as an off-white material in excellent yield and purity (280.3 g, 90%). δH (d6-DMSO, 300 MHz) 12.70 (1H, s), 8.35 (1H, dd), 7.85 (1H, dd), 7.40 (1H, dd), 4.25 (2H, s). LCMS (ES)+ RT 1.75 min, m/e 171.99 (M+1, Product).
- Thiophosgene (3.55 ml, 46.4 mmol) was added to a rapidly-stirred mixture of 2-fluoro-4-iodoaniline (10.0 g, 42.2 mmol) in CHCl3 (200 ml) and water (100 ml). The mixture was stirred at r.t. for 16 h. The organic phase was dried (Na2SO4) and concentrated in vacuo to give the title compound as an off-white crystalline solid (11.8 g, quant.). δH (DMSO-d6) 7.87 (1H, dd, J 1.8, 9.5 Hz), 7.63 (1H, ddd, J 1.0, 1.8, 8.4 Hz), 7.25 (1H, dd, J 8.2, 8.4 Hz).
- To a stirred solution of diisopropylamine (35.3 mL, 250 mmol) in anhydrous THF (200 mL) cooled to -15°C was added n-butyllithium (100 mL, 2.5M in hexanes, 250 mmol) slowly such that an internal temperature of between -10 and 0°C was maintained. The resultant mixture was stirred at room temperature for 15 minutes before being cooled to 0°C. The solution of lithium diisopropylamide was added via cannula to a rapidly stirred suspension of (2-chloropyridin-3-yl)acetic acid (Intermediate 3; 21.4 g, 125 mmol) in anhydrous THF (400 mL) at 0°C. The temperature of the reaction mixture was maintained at 0°C over the course of the addition. Upon complete addition of the lithium diisopropylamide solution the resultant bright yellow suspension was stirred at 0°C for 15 minutes. A solution of Intermediate 4 (34.9 g, 125 mmol) in anhydrous THF (200 mL) was then added to the reaction mixture via cannula and the mixture heated to 65°C for 18 hours. The reaction mixture was cooled and the volatiles removed in vacuo. The resultant brown gum was redissolved in THF (200 mL), cooled to 0°C and 10% aqueous acetic acid (500 mL) added slowly. Acetonitrile (-200 mL) was added slowly until a brown solid developed; the solid was isolated by filtration and washed with successive portions of diethyl ether and acetonitrile to give the title compound as a yellow crystalline solid (11.0 g, 21%). δH (DMSO-d6) 8.42 (1H, d, J 6.7 Hz), 8.22 (1H, m), 7.73 (1H, m), 7.61 (1H, m), 7.46 (1H, t, J 8.6 Hz), 7.35-7.31 (1H, m). Exchangeable protons were not observed. LCMS (pH 10) RT 1.82 minutes, ES+ 415 (M+H)+, ES- 413 (M-H)-.
- A suspension of Intermediate 5 (3 g, 7.2 mmol) in toluene (50 mL) was heated at reflux for 18 hours. After this time the solvent was removed in vacuo to afford the title compound as a pale brown solid (2.7 g, quant.). δH (CDCl3) 8.42 (1H, dd J 1.6, 4.7 Hz), 7.82 (1H, dd J 1.4, 8.1 Hz), 7.46 (2H, m), 7.27-7.18 (2H, m), 6.77 (1H, s), 6.25 (1H, s). LCMS (pH 10) RT 3.36 minutes, (ES+) 371 (M+H)+.
- A solution of Intermediate 6 (270 mg, 0.73 mmol) in DCM (25 mL) was cooled (acetone/CO2 bath) before chlorosulfonic acid (0.24 ml, 3.65 mmol) was added dropwise. The mixture was placed in an ice bath and stirred for 5 hours, before pyridine (1.2 mL, 14.6 mmol) and then pentafluorophenol (300 mg, 1.6 mmol) were added. After 18 hours the reaction mixture was partitioned between DCM (100 mL) and water (100 mL). The organic layer was dried (Na2SO4) and concentrated in vacuo and after chromatography (SiO2/DCM) gave the title compound as a white crystalline solid (395 mg. 88%). δH (CDCl3) 8.57 (1H, s), 8.43 (1H, m), 8.15 (1H, m), 7.62 (2H, m), 7.39-7.27 (2H, m). LCMS (pH 3) RT 3.93 minutes, (ES+) 617 (M+H)+.
- To a solution of Intermediate 7 (190 mg, 0.31 mmol) and pyridine (0.047 mL, 0.60 mmol) in DCM (5 mL) was added azetidin-3-ylmethylcarbamic acid tert-butyl ester (115 mg, 0.62 mmol) and the reaction stirred overnight at ambient temperature. After this time the reaction mixture was diluted with 30 mL of DCM, and washed with 2M HCl (2 x 25 mL) and water (25 mL). After drying (Na2SO4) and evaporating in vacuo, the residue was purified by chromatography (SiO2, 30% EtOAc in DCM) to afford the title compound as a white solid (150 mg, 78%). δH (CDCl3) 9.04 (1H, s), 8.39 (1H, dd, J 1.6, 4.7 Hz), 8.20 (1H, dd, J 1.6, 8.1 Hz), 7.58 (2H, m), 7.40 (1H, m), 7.31 (1H, dd, J 4.8, 8.2 Hz), 4.68 (1H, s), 3.95 (2H, dd, J 8.1, 8.1 Hz), 3.63 (2H, m), 3.25 (2H, m), 2.69 (1H, m), 1.41 (9H, s). LCMS (pH 3) RT 3.51 minutes, (ES+) 619 (M+H)+.
- Prepared from Intermediate 6 (200 mg, 0.541 mmol) by the method of Example 2 with N-BOC-piperazine (1.0 g, 1.08 mmol) to give after column chromatography (SiO2, 20% EtOAc in DCM) the title compound as an off-white solid (60 mg, 18%). δH (CDCl3) 9.00 (1H, s), 8.40 (1H, dd, J 1.4, 4.8 Hz), 8.16 (1H, dd, J 1.6, 8.2 Hz), 7.58 (2H, m), 7.38 (1H, dd, J 8.6, 8.6 Hz), 7.31 (1H, dd, J 4.7, 8.2 Hz), 3.53 (4H, t, J 4.9 Hz), 3.18 (4H, t, J 4.9 Hz), 1.43 (9H, s). LCMS (pH 10) RT 2.91 minutes, (ES+) 619 (M+H)+.
- 3-Oxoazetidine-1-carboxylic acid tert-butyl ester (500 mg, 2.9 mmol) was dissolved in ethanol (1.5 mL) and to this was added nitromethane (0.6 mL) and triethylamine (cat.). The reaction was stirred for eighteen hours and the solvent was then removed under reduced pressure to yield the title compound as a white solid (650 mg, 97%). δH (d6-DMSO) 6.42 (1H, s), 4.86 (2H, s), 4.04 (2H, d, J9.2 Hz), 3.75 (2H, d, J9.2 Hz), 1.39 (9H, s). LCMS (ES+) RT (pH 10) 1.73 min (M-H)- 231.
- Intermediate 10 (500 mg, 2.2 mmol) was dissolved in ethanol (40 mL) in a hydrogenation vessel and 10% palladium on charcoal (43 mg) was added. The vessel was charged with hydrogen to 50 psi and heated to 50°C. This was then stirred for 2 h and the catalyst was removed by filtering through a plug of celite. The solvent was removed under reduced pressure to yield a pale yellow oil. The intermediate was purified by chromatography on an amine column using 5% DCM/MeOH as the eluent to afford the BOC-protected amine as an off-white solid (306 mg, 68%). δH (d6-DMSO) 5.50 (1H, s), 3.73 (2H, d, J 8.5 Hz), 3.54 (2H, d, J 8.5 Hz), 2.60 (2H, s), 1.37 (9H, s). Some exchangeable protons were not observed. The intermediate BOC-protected amine was dissolved in DCM (10 mL) and trifluoroacetic acid (1 mL) added. The mixture was stirred for 1 hour at room temperature before the volatiles were removed in vacuo to give the title compound, which was used without further purification.
- To a solution of Intermediate 6 (60 mg, 0.16 mmol) in DCM (5 mL), cooled in a CO2/acetone bath, was added chlorosulfonic acid (200 mg, 1.72 mmol) dropwise. The reaction mixture was placed in an ice bath and stirred for a further 5 hours. After this time pyrrolidine (250 mg, 3.5 mmol) was slowly added and the reaction stirred for 18 hours at ambient temperature. The reaction mixture was diluted with DCM (25 mL) and washed with water (20 mL), 2M HCl (20 mL) and water (20 mL). The organic phases were dried (Na2SO4) and evaporated in vacuo. The product was recrystallised from acetonitrile/water to afford the title compound (30 mg, 37%) as an off-white solid. δH (CDCl3) 9.12 (1H, s), 8.38 (1H, dd, J 4.8, 1.5 Hz), 8.24 (1H, dd, J 8.1, 1.5 Hz), 7.57 (2H, m), 7.40 (2H, m), 3.38 (4H, t, J6.6 Hz), 1.89 (4H, t, J6.6 Hz). LCMS (pH 3) RT 3.95 minutes, (ES+) 504 (M+H)+.
- Intermediate 8 (140 mg, 0.23mmol) was treated with a 20% solution of TFA in DCM (5 mL). The reaction mixture was stirred for three hours at room temperature, before diluting with 25 mL of DCM and washing with NaHCO3 solution (25 mL) and then water (25 mL). The organic layer was dried (Na2SO4) and evaporated in vacuo to give the title compound as a white powder (89 mg, 75%). δH (DMSO-d6) 8.26 (1H, s), 8.08 (1H, dd, J 1.6, 4.7 Hz), 7.92 (1H, dd, J 1.6, 8.1 Hz), 7.66 (1H, dd, J 1.9, 10.1 Hz), 7.53 (1H, dd, J 2.0, 8.3 Hz), 7.23 (2H, m), 3.92 (2H, t, J 8.2 Hz), 3.65 (2H, m), 2.80 (2H, d, J 7.3 Hz), 2.54 (1H, m). Exchangeable protons were not observed. LCMS (pH 10) RT 2.73 minutes, (ES+) 519 (M+H)+.
- To a solution of Intermediate 7 (300 mg, 0.48 mmol) and pyridine (0.075 mL, 0.96 mmol) in DCM (5 mL) was added pyrrolidinyl-3(R)-carbamic acid tert-butyl ester (76 mg, 0.96 mmol) and the reaction was stirred overnight at ambient temperature. After this time the reaction mixture was diluted with DCM (35 mL), and washed with 2M HCl (2 x 25 mL) and water (25 mL). The organic phases were dried (Na2SO4), filtered and the solvents removed in vacuo to give a crude residue. Purification by column chromatography (SiO2, 25% EtOAc in DCM) gave the title compound as a white solid (300 mg, 100%). δH (CDCl3) 8.98 (1H, s), 8.30 (1H, dd, J 1.2, 4.6 Hz), 8.10 (1H, dd, J 1.2, 8.1 Hz), 7.50 (2H, m), 7.30 (1H, m), 7.27 (1H, dd, J 4.7, 8.2 Hz), 4.55 (1 H, br s), 4.11 (1H, s), 3.45 (2H, m), 3.20 (2H, m), 2.10 (1H, m), 1.70 (1H, m), 1.33 (9H, s). LCMS (pH 3) RT 3.54 minutes, (ES+) 619 (M+H)+.
- Example 3 (300 mg, 0.48 mmol) was treated with a 20% solution of TFA in DCM (5 mL). The reaction mixture was stirred for three hours at room temperature before being diluted with DCM (25 mL) and washed with NaHCO3 solution (25 mL) and water (25 mL). The organic layer was dried (Na2SO4) and evaporated in vacuo to give the title compound as an off-white powder (230 mg, 92%). δH (DMSO-d6) 8.15 (1H, dd, J 1.5, 4.7 Hz), 8.04 (1H, dd, J 1.5, 8.1 Hz), 7.70 (1H, dd, J 1.8, 10.1 Hz), 7.57 (1H, d, J 8.4 Hz), 7.33-7.24 (2H, m), 5.26 (2H, br s), 3.47 (2H, t, J6.5 Hz), 3.35 (2H, m), 2.99 (1H, m), 1.98 (1H, m), 1.59 (1H, m). One exchangeable proton was not observed. LCMS (pH 3) RT 1.92 minutes, (ES+) 519 (M+H)+.
- To a solution of Intermediate 7 (150 mg, 0.24 mmol) and pyridine (0.038 mL, 0.48 mmol) in DCM (5 mL) was added pyrrolidinyl-3(S)-carbamic acid tert-butyl ester (38 mg, 0.48 mmol) and the reaction mixture stirred overnight at room temperature. After this time the reaction mixture was diluted with DCM (35 mL) and washed with 2M HCl (2 x 25 mL) and water (25 mL). After drying (Na2SO4) and evaporation in vacuo, the residue was purified by chromatography (SiO2,25% EtOAc in DCM) to afford the title compound as an off-white solid (132 mg, 89%). δH (CDCl3) 8.98 (1H, s), 8.30 (1H, dd, J 1.6, 4.6 Hz), 8.10 (1H, dd, J 1.6, 8.1 Hz), 7.50 (2H, m), 7.30 (1H, m), 7.27 (1H, dd, J 4.7, 8.2 Hz), 4.55 (1H, br s), 4.11 (1H, s), 3.45 (2H, m), 3.20 (2H, m), 2.10 (1H, m), 1.70 (1H, m), 1.33 (9H, s). LCMS (pH 3) RT 3.56 minutes, (ES+) 619 (M+H)+.
- Example 5 (132 mg, 0.21 mmol) was treated with a 20% solution of TFA in DCM (5 mL). The reaction mixture was stirred for three hours at room temperature before being diluted with DCM (25 mL) and washed with saturated aqueous NaHCO3 solution (25 mL) and water (25mL). The organic layer was dried (Na2SO4) and evaporated in vacuo to give the title compound as an off-white powder (66 mg, 61 %). δH (DMSO-d6) 8.15 (1H, dd, J 1.5, 4.7 Hz), 8.04 (1H, dd, J 1.5, 8.1 Hz), 7.70 (1H, dd, J 1.8, 10.1 Hz), 7.57 (1H, d, J 8.4 Hz), 7.33-7.24 (2H, m), 5.26 (2H, br s), 3.47 (2H, t, J 6.5 Hz), 3.35 (2H, m), 2.99 (1H, m), 1.98 (1H, m), 1.59 (1H, m). One exchangeable proton was not observed. LCMS (pH 3) RT 1.92 minutes, (ES+) 519 (M+H)+.
- To a solution of Intermediate 9 (60 mg, 0.096 mmol) in 1,4-dioxane (5 mL) was added 4M HCl in 1,4-dioxane (10 mL) and the solution stirred at ambient temperature for 3 hours. The volatiles were then removed in vacuo to give the title compound as an off-white solid (50 mg, quant.). δH (DMSO-d6) 9.13 (1H, s), 9.02 (1H, s), 8.37 (1H, dd, J 1.5, 4.7 Hz), 8.11 (1H, dd, J 1.5, 8.2 Hz), 7.87 (1H, dd, J 1.8, 9.8 Hz), 7.70 (1H, dd, J 1.0, 8.3 Hz), 7.43 (2H, m), 3.40 (4H, m), 3.19 (4H, m). LCMS (pH 10) RT 3.60 minutes, (ES+) 519 (M+H)+.
- Prepared from Intermediate 7 (170 mg, 0.28 mmol) by the method of Example 3 with Intermediate 11 (100 mg, 0.94 mmol) to give after prep LC the title compound as a white solid (9 mg, 2%). δH (DMSO-d6) 8.24 (1H, s), 8.11 (1H, d, J 4.4 Hz), 7.95 (1H, m), 7.70 (1H, m), 7.57 (1H, m), 7.29-7.22 (2H, m), 5.85 (1H, s), 3.79 (2H, d, J 8.3 Hz), 3.61 (2H, d, J 8.3 Hz), 2.74 (2H, s). Some exchangeable protons were not observed. LCMS (pH 3) RT 2.00 minutes, (ES+) 535 (M+H)+.
- To a stirring mixture of Example 2 (160 mg, 0.31 mmol) and N,N-diisopropylethylamine (57 µL, 31 mmol) in DMF (5 mL) was added ethyl acrylate (51 µL, 0.31 mmol) and the mixture allowed to stir for 18 hours. After this time EtOAc (25 mL) was added to the reaction mixture which was then washed with brine (3 x 25 mL), dried (sodium sulfate) and then reduced in vacuo. The resulting oil was purified by column chromatography (SiO2, 50% DCM in EtOAc) to afford the title compound as a colourless oil (71 mg, 38%). δH (CDCl3) 8.97 (1H, s), 8.30 (1H, dd, J 1.6, 4.7 Hz), 8.12 (1H, dd, J 1.6, 8.2 Hz), 7.51 (2H, m), 7.33 (1H, dd, J 8.7, 8.7 Hz), 7.23 (1H, dd, J 4.7, 8.2 Hz), 4.04 (2H, q, J 7.2 Hz), 3.88 (2H, dd, J 8.0, 8.0 Hz), 3.55 (2H, dd, J 5.6, 8.0 Hz), 2.71 (2H, t, J 6.3 Hz), 2.64 (2H, d, J 7.3 Hz), 2.53 (1H, m), 2.33 (2H, t, J 6.3 Hz), 1.17 (3H, t, J 7.2 Hz). Exchangeable protons were not observed. LCMS (pH 10) RT 3.19 minutes, (ES+) 619 (M+H).
- To a stirring mixture of Example 2 (200 mg, 0.39 mmol) and N,N-diisopropyl-ethylamine (68 µL, 42 mmol) in DMF (5 mL) was added ethyl bromoacetate (43 µL, 0.39 mmol) and the mixture allowed to stir for 18 hours. After this time EtOAc (25 mL) was added to the reaction mixture which was then washed with brine (3 x 25 mL), dried (sodium sulfate) and then reduced in vacuo. The resulting oil was purified by column chromatography (SiO2, 50% DCM in EtOAc) to afford the title compound as a white solid (47 mg, 20%). LCMS (pH 3) RT 2.24 minutes, (ES+) 605 (M+H).
- Intermediate 3 (150 mg, 0.25 mmol) was dissolved in dichloromethane (6 mL) and triethylamine (75 µL, 0.50 mmol) and 3-hydroxyazetidine HCl salt (55 mg, 0.50 mmol) were added. The reaction mixture was stirred at ambient temperature under nitrogen for 18 hours. Dichloromethane (20 mL) was added and the solution washed with water (10mL), dried (Na2SO4) and concentrated in vacuo. The residue was triturated with diethyl ether (10 mL) to remove pentafluorophenol. The crude product was purified by prep HPLC to give after freeze-drying the title compound as a white solid (50 mg, 39%). δH (DMSO-d6) 8.27 (1H, s), 8.21 (1H, d, J 3.5 Hz), 8.00 (1H, dd, J 1.4, 8.3 Hz), 7.76 (1H, dd, J 1.8, 10.0 Hz), 7.61 (1H, d, J 8.3 Hz), 7.37-7.29 (2H, m), 5.73 (1H, br s), 4.36-4.27 (1H, m), 3.95 (2H, dd, J 6.7, 8.4 Hz), 3.54 (2H, dd, J 6.1, 8.4 Hz). LCMS (ES+) RT 2.84 minutes, pH 3 method, 506 (M+H)+.
- Intermediate 7 (150 mg, 0.25 mmol) was dissolved in dichloromethane (6 mL), and triethylamine (75 µl, 0.50 mmol) and (R)-3-hydroxypyrrolidine (44 mg, 0.50 mmol) were added. The reaction mixture was stirred at ambient temperature under nitrogen for 18 hours. Dichloromethane (20 mL) was added and the solution washed with water (10 mL), dried (Na2SO4) and concentrated in vacuo. The residue was triturated with diethyl ether (10 mL), then washed with a further portion of diethyl ether (5 mL) to give the title compound as a white solid (80 mg, 63%). δH (DMSO-d6) 9.08 (1H, br s), 8.33 (1H, d, J 3.4 Hz), 8.17-8.14 (1H, m), 7.84 (1H, dd, J 1.6, 9.9 Hz), 7.67 (1H, d, J 8.4 Hz), 7.49-7.39 (2H, m), 4.93 (1H, br s), 4.25-4.21 (1H, m), 3.41-3.34 (3H, m), 3.15-3.11 (1H, m), 1.93-1.71 (2H, m). LCMS (ES+) RT 2.88 minutes, pH 3 method, 520 (M+H)+.
- Intermediate 7 (150 mg, 0.25 mmol) was dissolved in dichloromethane (6 mL), and triethylamine (75 µl, 0.50 mmol) and azetidin-3-ylcarbamic acid tert-butyl ester (86 mg, 0.50 mmol) were added. The reaction mixture was stirred at ambient temperature under nitrogen for 18 hours. Dichloromethane (20 mL) was added and the solution washed with water (10 mL), dried (Na2SO4) and concentrated in vacuo. The residue was triturated with diethyl ether (10 mL), then washed with a further portion of diethyl ether (5 mL) to give the title compound as a white solid (140 mg, 95%). δH (DMSO-d6) 9.04 (1H, br s), 8.36 (1H, dd, J 1.5, 4.7 Hz), 8.09 (1H, dd, J 1.5, 8.2 Hz), 7.85 (1H, dd, J 1.9, 9.8 Hz), 7.70 (1H, dd, J 1.0, 8.4 Hz), 7.52-7.41 (3H, m), 4.22-4.19 (1H, m), 3.96 (2H, t, J 7.5 Hz), 3.63 (2H, t, J 7.5 Hz), 1.31 (9H, s). LCMS (ES+) RT 3.48 minutes, pH3 method, 605 (M+H)+.
- Example 15 (125 mg, 0.21 mmol) was dissolved in dichloromethane (3 mL). TFA (2 mL) was added and the reaction mixture was stirred at r.t. for 5 hours. After concentrating in vacuo, the residue was partitioned between ethyl acetate (100 mL) and sat. sodium carbonate solution (100 mL). The organic phase was dried (Na2SO4), and concentrated in vacuo to give the title compound as an off-white solid (65 mg, 63%). δH (DMSO-d6) 8.33 (1H, dd, J 1.6, 4.7 Hz), 8.08 (1H, dd, J 1.6, 8.2 Hz), 7.83 (1H, dd, J 1.9, 9.9 Hz), 7.70-7.66 (1H, m), 7.50-7.39 (2H, m), 4.74 (3H, br s), 3.94-3.89 (2H, m), 3.64-3.55 (1H, m), 3.41-3.33 (2H, m). LCMS (ES+) RT 2.67 minutes, pH 3 method, 505 (M+H)+.
Claims (15)
- A compound of formula (I), or a pharmaceutically acceptable salt, solvate or N-oxide thereof:
R1 represents hydrogen, halogen or C1-6 alkyl;
R2 represents halogen or C1-6 alkyl;
R3 represents -SO2NRbRc; and
Rb and Rc, when taken together with the nitrogen atom to which they are both attached, represent azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, thiomorpholin-4-yl, piperazin-1-yl, homopiperidin-1-yl, homomorpholin-4-yl or homopiperazin-1-yl, any of which groups may be optionally substituted by one or more substituents selected from C1-6 alkyl, hydroxy, hydroxy(C1-6)alkyl, C1-6 alkoxy, C1-6 alkoxy(C1-6)alkyl, amino(C1-6)alkyl, (amino)(hydroxy)(C1-6)alkyl, halogen, oxo, C2-6 alkylcarbonyl, carboxy, carboxy(C1-6)alkyl, C2-6 alkoxycarbonyl, C2-6 alkoxycarbonyl-(C1-6)alkyl, di(C1-6)alkylhydrazinylcarbonyl, amino, C1-6 alkylamino, di(C1-6)alkylamino, C2-6 alkylcarbonylamino, C2-6 alkoxycarbonylamino, C2-6 alkoxycarbonylamino(C1-6)-alkyl, C2-6 alkoxycarbonyl(C1-6)alkylamino(C1-6)alkyl, aminocarbonylamino, aminocarbonyl, C1-6 alkylaminocarbonyl, di(C1-6)alkylaminocarbonyl, aminosulfonyl, C1-6 alkylsulfonyl and C1-6 alkylaminocarbonyl(C1-6)alkyl. - A compound as claimed in claim 1 wherein the cyclic moiety -NRbRc represents azetidin-1-yl, pyrrolidin-1-yl or piperidin-1-yl, any of which groups may be optionally substituted by one or more substituents as defined in claim 1.
- A compound as claimed in claim 1 or claim 2 wherein the cyclic moiety -NRbRc is unsubstituted, or substituted by one or two substituents as defined in claim 1.
- A compound as claimed in any one of the preceding claims wherein the substituents on the cyclic moiety -NRbRc are selected from hydroxy, amino, amino-(C1-6)alkyl, C2-6 alkoxycarbonylamino and C2-6 alkoxycarbonyl(C1-6)alkylamino-(C1-6)alkyl.
- A compound as claimed in claim 4 wherein the substituents on the cyclic moiety -NRbRc are selected from hydroxy, amino, aminomethyl, tert-butoxycarbonyl-amino, ethoxycarbonylmethylaminomethyl and ethoxycarbonylethylaminomethyl.
- A compound as claimed in claim 1 wherein the cyclic moiety -NRbRc represents 3-hydroxyazetidin-1-yl, 3-aminoazetidin-1-yl, 3-(aminomethyl)azetidin-1-yl, 3-(aminomethyl)-3-hydroxyazetidin-1-yl, 3-(tert-butoxycarbonylamino)azetidin-1-yl, 3-(ethoxycarbonylmethylaminomethyl)azetidin-1-yl, 3-(ethoxycarbonylethylaminomethyl)-azetidin-1-yl, pyrrolidin-1-yl, 3-hydroxypyrrolidin-1-yl, 3-aminopyrrolidin-1-yl, 3-(tert-butoxycarbonylamino)pyrrolidin-1-yl or piperazin-1-yl.
- A compound as claimed in claim 7 wherein R12 represents bromo or iodo.
- A compound as claimed in claim 8 wherein R12 is iodo.
- A compound as claimed in claim 1 selected from the following:N-(2-fluoro-4-iodophenyl)-3-(pyrrolidin-1-ylsulfonyl)thieno[2,3-b]pyridin-2-amine;3-{[3-(aminomethyl)azetidin-1-yl]sulfonyl}-N-(2-fluoro-4-iodophenyl)thieno[2,3-b]-pyridin-2-amine;tert-butyl [(3R)-1-({2-((2-fluoro-4-iodophenyl)amino]thieno[2,3-b]pyridin-3-yl}-sulfonyl)pyrrolidin-3-yl]carbamate;3-{[(3R)-3-aminopyrrolidin-1-yl]sulfonyl}-N-(2-fluoro-4-iodophenyl)thieno[2,3-b]-pyridin-2-amine;tert-butyl [(3S)-1-({2-[(2-fluoro-4-iodophenyl)amino]thieno[2,3-b]pyridin-3-yl}sulfonyl)-pyrrolidin-3-yl]carbamate;3-{[(3S)-3-aminopyrrolidin-1-yl]sulfonyl}-N-(2-fluoro-4-iodophenyl)thieno[2,3-b]-pyridin-2-amine;N-(2-fluoro-4-iodophenyl)-3-(piperazin-1-ylsulfonyl)thieno[2,3-b]pyridin-2-amine hydrochloride;3-(aminomethyl)-1-({2-[(2-fluoro-4-iodophenyl)amino]thieno[2,3-b]pyridin-3-yl-sulfonyl)azetidin-3-ol;ethyl N-{(1-({2-[(2-fluoro-4-iodophenyl)amino]thieno[2,3-b]pyridin-3-yl}sutfonyl)-azetidin-3-yl]methyl}-beta-alaninate;ethyl N-{[1-({2-[(2-fluoro-4-iodophenyl)amino]thieno[2,3-b]pyridin-3-yl}sulfonyl)-azetidin-3-yl]methyl glycinate;1-({2-[(2-fluoro-4-iodophenyl)amino]thieno[2,3-b]pyridin-3-yl} sulfonyl)azetidin-3-ol;(3R)-1-({2-[(2-fluoro-4-iodophenyl)amino]thieno[2,3-b]pyridin-3-yl}sulfonyl)pyrrolidin-3-ol;tert-butyl-[1-({2-[(2-fluoro-4-iodophenyl)amino]thieno[2,3-b]pyridin-3-yl}sulfonyl)-azetidin-3-yl]carbamate; and3-[(3-aminoazetidin-1-yl)sulfonyl]-N-(2-fluoro-4-iodophenyl)thieno[2,3-b]pyridin-2-amine.
- A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1, or a pharmaceutically acceptable salt, solvate or N-oxide thereof, in association with a pharmaceutically acceptable carrier.
- The use of a compound of formula (I) as defined in claim 1, or a pharmaceutically acceptable salt, solvate or N-oxide thereof, for the manufacture of a medicament for the treatment and/or prevention of disorders for which the administration of a selective MEK inhibitor is indicated.
- A compound of formula (I) as defined in claim 1, or a pharmaceutically acceptable salt, solvate or N-oxide thereof, for use in therapy.
- A compound of formula (I) as defined in claim 1, or a pharmaceutically acceptable salt, solvate or N-oxide thereof, for use in the treatment and/or prevention of an inflammatory, autoimmune, cardiovascular, proliferative or nociceptive condition.
- A compound of formula (I) as defined in claim 1, or a pharmaceutically acceptable salt, solvate or N-oxide thereof, for use in the treatment and/or prevention of an oncological condition.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0714384.5A GB0714384D0 (en) | 2007-07-23 | 2007-07-23 | theraputic agents |
PCT/GB2008/002430 WO2009013462A1 (en) | 2007-07-23 | 2008-07-16 | Thieno-pyridine derivatives as mek inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2183253A1 EP2183253A1 (en) | 2010-05-12 |
EP2183253B1 true EP2183253B1 (en) | 2013-12-18 |
Family
ID=38512745
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08775964.3A Active EP2183253B1 (en) | 2007-07-23 | 2008-07-16 | Thieno-pyridine derivatives as mek inhibitors |
Country Status (4)
Country | Link |
---|---|
US (1) | US8350037B2 (en) |
EP (1) | EP2183253B1 (en) |
GB (1) | GB0714384D0 (en) |
WO (1) | WO2009013462A1 (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0601962D0 (en) | 2006-01-31 | 2006-03-15 | Ucb Sa | Therapeutic agents |
WO2009093008A1 (en) * | 2008-01-21 | 2009-07-30 | Ucb Pharma S.A. | Thieno-pyridine derivatives as mek inhibitors |
GB0811304D0 (en) * | 2008-06-19 | 2008-07-30 | Ucb Pharma Sa | Therapeutic agents |
CN102020651B (en) | 2010-11-02 | 2012-07-18 | 北京赛林泰医药技术有限公司 | 6-aryl amino pyridone formamide MEK (methyl ethyl ketone) inhibitor |
GB201201332D0 (en) | 2012-01-26 | 2012-03-14 | Imp Innovations Ltd | Method |
WO2014071183A1 (en) | 2012-11-02 | 2014-05-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of reducing adverse effects in a cancer patient undergoing treatment with a mek inhibitor |
EP3008073B1 (en) | 2013-06-11 | 2020-01-01 | Latvian Institute Of Organic Synthesis | Thieno[2,3-b]pyridines as multidrug resistance modulators |
WO2017033113A1 (en) | 2015-08-21 | 2017-03-02 | Acerta Pharma B.V. | Therapeutic combinations of a mek inhibitor and a btk inhibitor |
CN109928983B (en) * | 2015-12-31 | 2021-06-29 | 四川大学 | 2-oxadiazole-3-aminothieno [2,3-b ] pyridine derivative and preparation method and application thereof |
US11178871B2 (en) | 2016-07-26 | 2021-11-23 | Basf Se | Herbicidal pyrimidine compounds |
WO2018019765A1 (en) | 2016-07-27 | 2018-02-01 | Basf Se | Herbicidal pyrimidine compounds |
WO2018019574A1 (en) | 2016-07-28 | 2018-02-01 | Basf Se | Herbicidal pyrimidine compounds |
CN106366034B (en) * | 2016-08-17 | 2019-09-03 | 南京红太阳生物化学有限责任公司 | A kind of preparation method of 3-Pyridineacetic Acid hydrochloride |
WO2018213807A1 (en) * | 2017-05-19 | 2018-11-22 | Nflection Therapeutics, Inc. | Fused heteroaromatic-aniline compounds for treatment of dermal disorders |
WO2019121373A1 (en) | 2017-12-20 | 2019-06-27 | Basf Se | Herbicidal pyrimidine compounds |
WO2019121374A1 (en) | 2017-12-20 | 2019-06-27 | Basf Se | Herbicidal pyrimidine compounds |
WO2019121352A1 (en) | 2017-12-20 | 2019-06-27 | Basf Se | Herbicidal pyrimidine compounds |
JP2022513089A (en) * | 2018-11-20 | 2022-02-07 | エヌフレクション セラピューティクス インコーポレイテッド | Arylaniline and heteroarylaniline compounds for the treatment of skin cancer |
US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6232320B1 (en) * | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
YU2503A (en) | 2000-07-19 | 2006-05-25 | Warner-Lambert Company | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
EP1482944A4 (en) | 2002-03-13 | 2006-04-19 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
CN101486682B (en) | 2002-03-13 | 2013-08-14 | 阵列生物制药公司 | N3 alkylated benzimidazole derivatives as MEK inhibitors |
GB0214268D0 (en) | 2002-06-20 | 2002-07-31 | Celltech R&D Ltd | Chemical compounds |
CL2003002287A1 (en) * | 2002-11-25 | 2005-01-14 | Wyeth Corp | COMPOUNDS DERIVED FROM TIENO [3,2-b] -PIRIDINA-6-CARBONITRILOS AND TIENEO [2,3-b] -PIRIDINA-5-CARBONITRILS, PHARMACEUTICAL COMPOSITION, PROCEDURE OF PREPARATION AND INTERMEDIARY COMPOUNDS, AND THEIR USE IN THE TREATMENT OF CANCER, APOPLEJIA, OSTEOPOROSIS |
EP1638979A1 (en) * | 2003-06-20 | 2006-03-29 | Celltech R & D Limited | Thienopyridone derivatives as kinase inhibitors |
AU2004249495A1 (en) | 2003-06-20 | 2004-12-29 | Ucb Pharma S.A. | Thienopyridone derivatives as kinase inhibitors |
US20050049276A1 (en) | 2003-07-23 | 2005-03-03 | Warner-Lambert Company, Llc | Imidazopyridines and triazolopyridines |
DE602004023207D1 (en) | 2003-07-24 | 2009-10-29 | Warner Lambert Co | BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS |
US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
AU2004270394A1 (en) * | 2003-09-10 | 2005-03-17 | Gpc Biotech Ag | Heterobicyclic compounds as pharmaceutically active agents |
SI1682138T1 (en) | 2003-11-19 | 2011-04-29 | Array Biopharma Inc | Heterocyclic inhibitors of mek |
US7217723B2 (en) * | 2004-02-02 | 2007-05-15 | Eisai Co., Ltd. | Heterocyclic compound having oxime group |
CA2620864A1 (en) * | 2005-09-01 | 2007-03-08 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
ATE504565T1 (en) | 2005-10-07 | 2011-04-15 | Exelixis Inc | AZETIDINES AS MEK INHIBITORS IN THE TREATMENT OF PROLIFERATIVE DISEASES |
GB0601962D0 (en) * | 2006-01-31 | 2006-03-15 | Ucb Sa | Therapeutic agents |
TW200808769A (en) | 2006-04-18 | 2008-02-16 | Astrazeneca Ab | Therapeutic compounds |
GB0616214D0 (en) * | 2006-08-15 | 2006-09-27 | Ucb Sa | Therapeutic Agents |
WO2009093008A1 (en) * | 2008-01-21 | 2009-07-30 | Ucb Pharma S.A. | Thieno-pyridine derivatives as mek inhibitors |
GB0811304D0 (en) * | 2008-06-19 | 2008-07-30 | Ucb Pharma Sa | Therapeutic agents |
-
2007
- 2007-07-23 GB GBGB0714384.5A patent/GB0714384D0/en not_active Ceased
-
2008
- 2008-07-16 EP EP08775964.3A patent/EP2183253B1/en active Active
- 2008-07-16 WO PCT/GB2008/002430 patent/WO2009013462A1/en active Application Filing
-
2010
- 2010-01-22 US US12/691,842 patent/US8350037B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US8350037B2 (en) | 2013-01-08 |
EP2183253A1 (en) | 2010-05-12 |
WO2009013462A1 (en) | 2009-01-29 |
US20100179124A1 (en) | 2010-07-15 |
GB0714384D0 (en) | 2007-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2183253B1 (en) | Thieno-pyridine derivatives as mek inhibitors | |
EP1981892B1 (en) | Thieno-pyridine derivatives as mek inhibitors | |
US8487101B2 (en) | Thieno-pyridine derivatives as MEK inhibitors | |
US8637491B2 (en) | Thieno-pyridine derivatives as MEK inhibitors | |
US8338592B2 (en) | Fused thiazole derivatives as kinase inhibitors | |
US8637543B2 (en) | Quinoline derivatives as kinase inhibitors | |
EP2346878B1 (en) | Fused pyridine derivatives as kinase inhibitors | |
CA2776028A1 (en) | Pyrrolo[2,3-d]pyrimidine compounds | |
WO2010061180A1 (en) | Quinoline derivatives as p13 kinase inhibitors | |
WO2009093009A1 (en) | Fused tricyclic thiophene derivatives as mek inhibitors | |
JP2011504164A (en) | Condensed thiazole derivatives as kinase inhibitors | |
MX2008009610A (en) | Thieno-pyridine derivatives as mek inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20100223 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
17Q | First examination report despatched |
Effective date: 20120711 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20130710 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA MK RS |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 645593 Country of ref document: AT Kind code of ref document: T Effective date: 20140115 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602008029418 Country of ref document: DE Effective date: 20140213 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: VDEP Effective date: 20131218 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140318 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131218 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131218 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131218 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131218 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 645593 Country of ref document: AT Kind code of ref document: T Effective date: 20131218 |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131218 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131218 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140418 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131218 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131218 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131218 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131218 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131218 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131218 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131218 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131218 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140418 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131218 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602008029418 Country of ref document: DE |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131218 |
|
26N | No opposition filed |
Effective date: 20140919 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602008029418 Country of ref document: DE Effective date: 20140919 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140716 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131218 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 8 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20140716 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131218 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131218 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 9 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131218 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140319 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131218 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20131218 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20080716 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 10 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20220606 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20220609 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20220531 Year of fee payment: 15 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20220801 Year of fee payment: 15 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230421 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602008029418 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20230716 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20240201 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230731 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230716 |